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ABSTRACT
STRUCTURE-FUNCTION STUDIES OF THE cAMP-DEPENDENT 
PROTEIN KINASE IN  VITRO AND IN INTACT CELLS
Gary Z. Morris 
Old Dominion University, 2006 
Director: Dr. Stephen J. Beebe
There are 518 protein kinase genes in the human genome; this constitutes about
1.7% of all human genes. The cAMP-dependent protein kinase (PKA) serves as the 
prototypic model for the study of kinases because it contains a conserved catalytic core 
shared with all eukaryotic kinases, it is the simplest kinase, and it is one of the best- 
characterized serine/threonine kinases. PKA is ubiquitous in mammals and regulates 
multiple physiological mechanisms such as the cell cycle, apoptosis, cell motility, energy 
metabolism, and gene transcription through a well-defined intracellular signaling 
pathway. While PKA clearly has a central physiological role it is still unclear how PKA 
mediates multiple physiological mechanisms at the cellular level. Four approaches were 
used to explore this question using two PKA catalytic subunits, C a and Cy, which share 
83% identity in primary structure but differ in function. The first approach sought to 
identify differences in primary structure between Cy and C a, which may define 
functional differences between them. To this end chimeras were generated, swapping the 
carboxyl and amino termini between C a and Cy and were evaluated for functionality
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through CREB-mediated reporter assays. Wild type C a and Cy induced CREB-mediated 
transcriptional activation, but the chimeras failed to exhibit any activity. The second 
approach sought to characterize phosphorylation differences between purified PKA-Cy 
and PKA-Ca that defines their physiological function. Two novel phosphorylation sites 
were identified on both isoforms by tandem mass spectrometry analysis (Cy S14 and 
Ca/Cy S259). It was also determined that Cy expressed in Sf9 insect cells, like C a 
expressed in mammalian cells, is phosphorylated at T 197 and S3 3 8  and the modification 
at T197 is important to the function of both isoforms. The third approach sought to 
characterize the kinetic mechanism of PKA-Cy through determination of the rate for the 
reaction-limiting step, which was found to be 9-times slower than that o f Ca. The final 
approach sought to identify Cy expression in the cell through the use of a new Cy-specific 
antibody. Cy expression was identified following differentiation o f U-937 cells 
suggesting a novel function for Cy in the cell.
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1CHAPTER I
SIGNIFICANCE, SPECIFIC AIMS AND BACKGROUND
SIGNIFICANCE
There are 518 protein kinase genes in the human genome (2); this constitutes about
1.7% of all human genes (2). Kinases allow physiologic extracellular stimuli to elicit 
specific cellular response through signal transduction. The cAMP-dependent protein 
kinase (PKA) serves as the prototypic model for the study of kinases because it contains a 
conserved catalytic core shared with all eukaryotic kinases; it is the simplest kinase; and 
it is one o f the best-characterized serine/threonine kinases (3). PKA is ubiquitous in 
mammals (4-6) and regulates multiple physiological mechanisms such as the cell cycle 
(7), apoptosis (8 ), cell motility (9), energy metabolism (10), and gene transcription (11) 
through a well-defined intracellular signaling pathway (12,13). Deregulation of PKA is 
found in several diseases including Carney complex (14,15), Systemic Lupus 
Erythematosus (16,17), breast cancer (18), and prostate cancer (19). PKA knockout mice 
demonstrate deficiencies in neuronal pathways including decreased sensitivity to 
nocioceptive responses and alterations to synaptic plasticity (4). While PKA clearly has a 
central physiological role it is still unclear how PKA mediates multiple physiological 
mechanisms at the cellular level.
The m odel for this dissertation is the Journal o f  B io log ica l Chemistry.
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2SPECIFIC AIMS
cAMP-dependent protein kinase (PKA) mediates multiple physiological functions 
including hormone secretion, energy metabolism, apoptosis, and cellular differentiation in 
response to physiological stimuli. Thus, it is clear that PKA function is crucial to normal 
cell physiology and homeostasis. Therefore understanding the roles of PKA in the cell is a 
focus of ongoing scientific research. To this end, there is a large body o f scientific literature 
focusing on two of the PKA catalytic (C) subunits, C a and Cp. However less research has 
been done on the third PICA C-subunit, Cy. Recently we established that C a and Cy, while 
sharing sequence homology (83% identity in protein primary sequence), do not mediate 
transcription through the same promoter sequence or transcription factors and differ in their 
phosphorylation efficiency for multiple substrates tested (20). Research outlined in this 
dissertation was performed to determine structure-function differences between C a and Cy 
that explain how they mediate transcription through different mechanisms and why they 
differ in their catalytic measurements.
Specific Aim 1: To identify differences in primary structure between PKA-Cy and 
PKA-Ca that defines their physiological function in intact cells. Our hypothesis is that 
differences in C a and Cy primary structures are responsible in part for differential 
transcriptional regulation. Co-transfections of wild-type and mutated C-subunits with a 
PKA-selective reporter-vector will be used to characterize and correlate the C-subunit 
structure with their function.
Specific Aim 2: To characterize post-translational differences between purified 
PKA-Cy and PKA-Ca that defines their physiological function. Our hypothesis is that 
differences in Km and Vmax for physiological substrates are attributed in part to post-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
translational differences between C a and Cy. Liquid chromatography-tandem mass 
spectrometry analysis of purified recombinant histidine-labeled C a and Cy will be used to 
characterize post-translational phosphorylation differences between the C-subunits.
Specific Aim 3: To characterize the kinetic mechanism for PKA-Cy through 
determination of the rate constants for each catalytic step of the phosphotransferase 
reaction. Our hypothesis is that Cy functions through the same kinetic mechanism as C a 
but has slower rate constants. Stopped-flow analysis of purified recombinant proteins will 
be used to characterize pre-steady state kinetics necessary for establishing rate constants 
for each catalytic step.
The results presented in this dissertation suggest that one mechanism by which 
PKA mediates multiple physiological mechanisms within the cell is through expression of 
multiple isoforms. Here we focused on the two most divergent catalytic subunits, C a and 
Cy to study this mechanism. The following is a brief background introducing the kinase 
enzyme along with some background on PKA that 1) coincide with the specific aims 
outlined in this section, 2) coincide with work proposed for my Porter Physiology 
Fellowship and 3) coincide with different manuscripts that have either been published, 
submitted or in preparation for submission. Each of the following chapters will contain a 
more specific background pertaining to the focus of that chapter.
BACKGROUND
Protein kinases are an evolutionarily conserved protein fam ily- A  kinase is an 
enzyme that catalyzes the hydrolysis of the y-phosphate (the terminal phosphoryl group) on 
a nucleotide triphosphate (NTP) and the covalent binding of this phosphate to a target 
substrate. The Enzyme Commission o f  the International Union o f  Biochemistry and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Molecular Biology name for a kinase is a phosphotransferase. The term kinase is a lay-term 
derived from the Greek word kinein, which means to move towards1. In the context of the 
kinase the name refers to the movement of the phosphoryl group from NTP to the target 
substrate by the kinase. Figure 1 shows a timeline identifying important events related to 
the study of the kinase enzyme in the past century, including the “purification” of 
phosphorylase kinase in 1943, the first characterization of a kinase, casine kinase (now 
casine kinase 2), in 1954 and the description of the human kinome in 2002. The human 
genome contains at least 663 kinase genes (21). O f these, 518 are protein kinases, about 
half the number initially predicted (2, 22). Thus, almost 2% of the human genome is 
dedicated to the expression of this protein family suggesting that the function of this protein 
is very important to mammals (2). Protein kinases have been divided into eight distinct 
groups based on their structure and function (AGC: containing PKA, PKG, PKC families; 
CK1: casein kinase 1 group; STE: homologous to yeast sterile 7, sterile 11, sterile 20 
kinases group; TKL: tyrosine kinase-like group; TK: tyrosine kinase group; CMGC: 
containing CDK, MAPK, GSK3, CLK families, and CAMK: calcium/calmodulin- 
dependent kinase group) (2 ). Figure 1 also shows how the study of kinases has increased in 
an exponential manner over the last forty years, based on the number o f yearly publications 
found in Entrez PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi). Research seems 
to be nearing a plateau, which may indicate that the rate at which scientist are able to study 
kinases, generate results and publish them using current technology is reaching a limit. The 
time line presented in Figure 1 also suggests that key basic science discoveries in the kinase 
field seem to be made about every nine years.
1 B ased  on a personal em ail com m unication from Tony Hunter. P lease see A ppendix A.
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F ig . 1. Time line showing discovery and publication trends in the kinase field.
Arrows point to important contributions to the kinase field on the time line, which 
covers 64 years (x-axis). The bars show publications within a given year, sampled 
every four years (y-axis).
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6Kinases utilize an evolutionarily conserved mechanism and are found in organisms of all 
three Domains of life: Archaea, Bacteria and Eucarya (23-25). Kinases are placed in broad 
groups that include protein kinases, which phosphorylate proteins, and lipid kinases, which 
phosphorylate lipids generating secondary messengers in the cell. Some kinases, referred to 
as ‘small molecule kinases,’ do not fit in any of these groups such as hexokinase 
(phosphorylates glucose), choline kinase (phosphorylates choline) or ethanolamine kinase 
(phosphorylates ethanolamine) (26). Kinases are also classified based on the nature of their 
substrate. These classifications include serine/threonine kinases, tyrosine kinases, histidine 
kinases, and antibiotic kinases, which are bacterial kinases, associated with bacterial 
antibiotic resistance and found to be closely associated to eukaryotic serine/threonine 
kinases (27). The prevalent kinases found in the Eukaryotes are the serine/threonine and 
tyrosine protein kinases (2). In recent years serine/threonine protein kinases have also been 
identified in bacteria and archaeabacteria (25,28). Histidine protein kinases are found in 
bacteria, archaeabacteri, plants, fungi, and slime mold as part o f a two-component system, 
where the kinase autophosphorylates on a histidine residue (the first component), transfers 
this phosphoryl to an aspartate on the effector domain (the second component) leading to 
the response to extracellular stimuli (25,28,29).
While the structure and chemical nature of the substrates differ between the kinase 
groups, most protein kinases share sequence and structural homology through their 
catalytic core, which consists of approximately 250-300 amino acids (23). O f the 518 
protein kinases in the human genome, 478 share homology in this region (2). 
Mitochondrial pyruvate dehydrogenase kinases have been found to share sequence and 
structural homology with prokaryotic histidine kinases (30). Histidine kinases and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
eukaryotic kinases share some sequence homology through the nucleotide binding domain 
and structural homology through the small lobe (29), suggesting that all kinases evolved 
from a ‘protokinase’ present prior to the divergence of the three domains of life(29). This 
hypothesis depends on the methods and criteria used to classify sequence homology and 
not all literature agrees that there is homology between the atypical prokaryotic kinases and 
eukaryotic kinases (23). Furthermore, not all eukaryotic kinases share sequence homology 
as demonstrated by a group of 40 kinases in the human kinome classified as atypical 
kinases because they lack sequence homology with the rest of the kinases (2). However all 
o f these kinases have been reported to have phospho-transferase activity and many share 
structural homology with typical eukaryotic kinases. The homology of kinases among 
organisms and Domains will be easier to discern once kinomes are identified for all 
organisms used in these comparison studies. Such work is presently underway in 
archeabacteria (25). The presence of homologous kinases among Domains is more likely to 
be due to horizontal transfer between organisms than to independent evolutionary pathways 
(30). The transfer of a phosphate group as a signal in the organism has been conserved 
through the diverse groups of kinases found in all three life Domains, making the theory of 
a protokinase very attractive. The evolutionarily conserved nature o f the protein kinase 
family allows for structure-function relationship characterization of this group through use 
of structurally simple members of this family.
The best-characterized protein kinase is the cAMP-dependent protein kinase (PKA, 
EC 2.7.1.37) (31). About 5% of the nearly 340,000 papers published on kinases found on 
Entrez PubMed are on PKA and, as Figure 1 demonstrates, PKA was the first for many 
developments in the kinase field. PKA was the first kinase for which a linear structure was
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
determined through a molecular biology approach, allowing for the generation of 
recombinant PKA and its subsequent characterization through recombinant protein 
technology (32). PKA was also the first kinase to be crystallized, allowing for its structure to 
be elucidated (33). PKA has a relatively simple structure, consisting of 350 amino acids 
including the 280 residues that constitute the conserved kinase catalytic core along with 70 
more amino acids, which also participate in the catalytic function of the enzyme. The PKA 
catalytic subunit consists of a bilobal structure shared by all protein kinases (33). The 
combined knowledge of PKA kinetics and structure have contributed to the present 
understanding of the kinase catalytic mechanism (34-38). Because of this wealth of 
information the PKA catalytic subunit serves as a template for the structural classification of 
all kinase domains (23,39,40) and an excellent model to study kinase structure-function 
relationships.
PKA is very important to organism physiology- PKA is present at varying 
concentrations in all tissue types (41-43) and exists in the cell as an inactive tetrameric 
holoenzyme composed of a regulatory (R) subunit dimer and two monomeric C subunits 
(31,44). The holoenzyme (R2C2) can be classified into types I and II PKA determined by 
the R subunit isoform present in the holoenzyme. There are four known Homo sapiens 
genes for the R subunit: RIa, Rip, R lla, and RIIp. Classically, PKA type I elutes from a 
DEAE column at concentrations below 0.1 M NaCl and type II elutes at concentrations 
greater than 0.1 M NaCl (44). There are four genes for the C-subunit expressed in Homo 
sapiens: Ca, Cp, Cy and PrKX (45,46). The PKA catalytic subunits are members o f the 
AGC serine/threonine kinase group (2), and phosphorylate hundreds o f substrates involved 
in numerous physiological processes (1). Each of the C-subunit isoforms is expressed from
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
an independent gene: Ca, 19pl3.1; Cp, lp36.1; Cy, 9ql3; and PrKX, Xp22.3 (47,48) and 
they all exhibit different selective tissue expression. C a is ubiquitously expressed, Cp is 
expressed in neuronal tissue, Cy has only been properly identified in the testes, and PrKX is 
expressed ubiquitously (4,41,45,46). Human C a and CP share the highest degree of 
homology in their primary amino acid sequence (93% identity) and have multiple splice 
variants (49-52). C a and Cy are also highly homologous exhibiting 83% identity while Cp 
and Cy exhibit 79% identity (45). PrKX shares the least amount o f homology with C a 
(53% identity). Activation of PKA C-subunits is cAMP-dependent. The level o f cAMP in a 
cell is controlled through G-protein coupled protein receptors, which stimulate or inhibit 
adenylyl cyclase, modulating the synthesis of cAMP from ATP in response to hormone 
agonist (Figure 2) (53). cAMP levels in the cell are also regulated by cyclic nucleotide 
phosphodiesterases (PDEs) (Figure 2). PDEs hydrolyze cyclic nucleotides (e.g. cGMP and 
cAMP) to 5’-nucleotide monophosphates, eliminating the functional structure of the second 
messenger required to bind to its target (e.g. PKG and PKA). There are 11 known PDE 
families (PDE1-11), which vary in their specificities for cAMP and cGMP. O f the eleven
4 cAMP + R2C2 (inactive) < 4 cAMP*R2 + 2C (active) (1)
family members, PDE4, 7 and 8  are specific for cAMP. Once cAMP binds the R subunits
(2 cAMP molecules: 1 R subunit), which have a high affinity for cAMP (54-56), the R-
subunits’ affinity for the catalytic (C) subunits decreases by six orders of magnitude (13).
Thus, at very low levels of cAMP, the steady state favors formation of the holoenzyme
(Equation 1). In the presence of increasing levels of cAMP, the steady state shifts toward
dissociation of the holoenzyme (Equation 1).
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Hormone
CPR
Phosphorylation o f  target proteins itahe  
membrane and cytosol: \
P yruvate  k inase , R a f  1, A q u ap o rin -2 . . .  \’DE5
cAMP
Diffuse to the nucleus to 
induce transcriptional 
activation:
CREB and CREM
(PKA holoenzyme)
F ig . 2. PKA intracellular signal transduction pathway. Hormones that 
bind G-protein coupled receptors (GCPR) either activate or inhibit adenylyl 
cyclase (AC) which generates cAMP, which binds the R-subunits of the PKA 
holoenzyme, releasing the C-subunits, which are now free to propagate the 
signal transduction through phosphorylation of select substrates ( 1 ).
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Kinases are catalytic so only a few active kinases are required to propagate a signal for a 
given agonist and in most cases the duration of this activity is transient, lasting for as long as 
the agonist is bound to its receptor or that ligand-receptor complex is functional. A disease 
state is often associated with deregulation of a kinase either because the kinase cannot be 
activated or inactivated in response to its biological trigger. Determining the role or impact 
of PKA on organism development and disease through knock out (KO) models has proven 
tricky as there are multiple C-subunit isoforms, thus the KO of one gene often leads to 
compensation by other isoforms. However, 73% of C a KO mice do not survive beyond 
weaning, suggesting that this isoform is very important to the organisms development (57).
The remaining 27% that survived did so in part through compensating for the loss of 
C a with increased Cp expression, but still suffered from developmental defects (4). While 
KO of C a is deleterious in most cases, KO of Cp has no deleterious effect on mouse 
development (58), suggesting that this isoform has a different function from C a and that its 
role is not as dominant in the organism’s development. Similar trends are observed with the 
R-subunits, where KO of R a  isoforms leads to developmental defects and KO Rp isoforms 
have little or no impact on the organism’s development (4), but often leads to the onset of 
neurological dysfunctions (59,60). These animal models demonstrate that each PKA 
isoforms has different functions in the development of the organism, where C a has a 
dominant role in development and Cp has tissue specific functions and compensates for the 
loss of the dominant isoforms. Studies of Cy in KO mice cannot be performed as this is a 
primate specific isoform (45). Thus it is difficult to extrapolate from these studies the role 
Cy may have in organism development. While KO models have not been used to study 
PrKX, it has been demonstrated that PrKX is also important in neuronal differentiation (61).
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Diseases that manifest deregulation of PKA are rare, but include colon, breast and 
prostate cancer (18,62-64), systemic lupus erythematosus (16,17), Cushing’s syndrome 
(65), acromegaly, Carney complex (6 6 ), XX male and Swyer’s syndromes (48). What is 
observed in cancer is an increase in R-subunit expression (64), which would lead to 
increased suppression of C-subunit activity in response to cAMP. This may explain why 
extracellular C-subunit is detected in transformed tissue culture cell lines (62) where it is 
likely that the cell is trying to compensate for diminished cAMP-response due to the 
increase in RI expression by increasing C-subunit expression. This process may continue 
until it becomes deregulated. But caution should be exerted when interpreting these results, 
as they were preformed with tissue culture cell models where extracellular detection of the 
C-subunit may be due simply to the inadvertent lysis of a few cells and not to the secretion 
of the C-subunit from intact cells, something that has not been properly addressed in the 
published work on the subject. Nevertheless, these studies do imply that overexpressed, 
cAMP-independent deregulation of the C-subunit may contribute to the progression of 
cancer. Further evidence for this hypothesis is that ectopic expression o f the C-subunit in a 
prostate cancer cell line, LNCaP, is sufficient to induce neuroendocrine differentiation 
associated with the progression of prostate cancer (63).
Cushing’s, acromegaly, and Camey complex are endocrine diseases associated with 
mutations to R Ia that render expression of a non-functional R-subunit (67). This mutated RI 
subunit would decrease regulation of C a in the cell, making Ca-function cAMP- 
independent. XX male and Swyer’s syndromes are associated with ectopic recombination of 
PrKX in the X and Y chromosomes during development (48), which could lead to the 
incorrect expression of this gene during development. Each of these diseases clearly
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illustrates that, as with any kinase, the PKA catalytic subunits need to be carefully regulated 
within the cell and that deregulation of this protein has detrimental effects on the organism’s 
homeostasis.
PKA is regulated through transcription, translation, post-translation and 
pseudosubstrates- PKA function is regulated by intracellular levels o f cAMP, but PKA is 
also regulated through other mechanisms. The promoters for all the C-subunits are 
TATA-less, GC rich promoters with multiple start sites (47), which suggest that 
regulation of these enzymes is under “housekeeping” mechanisms (68,69) associated 
with cell and tissue specific expression (70). Expression of both PKA R- and C-subunits 
is also regulated at the mRNA and protein level. C a and CP gene expression is also 
regulated through splicing as each has several splice variants, C a l , Cs/Ca2, C pl, Cp2 
and Cp3, which are expressed in a cell type selective manner (52,71,72). Unlike C a, CP, 
or PrKX, Cy is an intronless retroposon gene that appeared in the human genome forty 
million years ago (73), thus Cy is not expected to have any splice variants and makes Cy 
the only known example of a primate specific PKA gene.
The regulation of PKA also occurs through the R-subunits at the mRNA level, 
which has been studied selectively in T- and B-cells, sertoli, L6  myoblast and lymphoid 
cells stimulated to undergo cAMP-induced differentiation. RI mRNA is constitutively 
expressed in L6  myoblast cells, thus regulation of this isoform occurs at the protein level
(74). In T and B cells low levels of RI-mRNA are observed along with high levels of RI- 
protein, and high levels o f RII-mRNA and protein expression are observed suggesting 
different regulatory mechanisms for mRNA for each R-subunit isoform in this cell type
(75). Regulation of RII in sertoli and lymphoid cells differs between R lla  and RIip,
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where RIIp mRNA levels do not change between differentiated and undifferentiated 
cells, but R lla  mRNA levels increase during cAMP-induced differentiation (76-78). 
Overall, regulation of RI expression is favored at the protein level and RII expression 
regulation seems to vary depending on the isoform and tissue type.
The R and C subunits are stabilized by formation of the holoenzyme, as the half- 
lives in the cell for each is twice as long as in the absence of cAMP (in the holoenzyme), 
than in its presence (79,80). This suggests that degradation o f the protein by ubquitin- 
mediated pathways is another regulatory mechanism of cAMP-dependent pathways (74). 
Both C and R subunits also undergo post-translational modifications, which modify their 
function. RII, but not RI, is phosphorylated at R lla  S95 or RII (I SI 12 decreasing its 
affinity for the C-subunit (reviewed in (81)). C a is phosphorylated at T197 and 
myristylated at glycine 1 (82,83). Phosphorylation on the catalytic loop at C a T197 is a 
necessary modification for kinase function, which is conserved among most kinases (84-86). 
In the case of C a this modification increases its catalytic activity 100-fold (87). 
Myristylation of C a increases the stability of the enzyme, as the myristate moiety folds into 
a C a hydrophobic pocket, which has the effect of increasing the protein’s melting 
temperature, a measure of increased stability (83).
Another regulatory mechanism for PKA is through pseudosubstrates, competitive 
inhibitor proteins that contain the PKA phosphorylation sequence motif (R-x-x-S/T), but 
have an alanine instead of a serine or threonine and thus cannot be phosphorylated by the C- 
subunit. The R-subunits and protein kinase inhibitor (PKI) are the two known 
pseudosubstrates for the C-subunits. RII is phosphorylated by the C-subunit following 
dissociation of the holoenzyme, so it still serves as C-subunit inhibitor.
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Interaction of the C-subunits with the R-subunits to form the holoenzyme sequesters 
and maintains the C-subunits localized in the cell cytosol (8 8 ). In the presence of cAMP, the 
C-subunits dissociate from the holoenzyme. Once released the C-subunits are free to 
phosphorylate available substrates in the cell membrane and cytosol and to diffuse into the 
nucleus (8 8 ) where they can phosphorylate transcription factors (Figure 2) (1). PKI inhibits 
and exports the C-subunits from the nucleus terminating its regulation of transcription 
factors (89).
There are several mechanisms by which PKA may regulate multiple cellular 
functions- By catalyzing the transfer of the NTP gamma-phosphate to a protein substrate, 
the kinase is modifying and altering the phosphoacceptor’s function, propagating and/or 
modifying signal cascades within the cell and regulating the cell’s function in response to 
extracellular signals (90). Kinases are central to most, if  not all, of the cell’s functions. 
Examples of this include cyclin-dependent kinases, which regulate the cell cycle (91), 
receptor associated tyrosine kinases, such as JAK which allow the cell to respond to 
interleukins during inflammatory responses of the immune system (92), and the MAPK 
kinase family, one of the best studied kinase signal cascades which regulate the cell’s 
response to growth factors (93). In all of these examples, the kinase is part of a system 
involving ligand (hormones), receptor and effector proteins (kinases), which are able to 
regulate multiple cellular functions. Kinases are central to the cell’s ability to function as 
both the unit that is the cell and as part of the collective that forms organs and the organism. 
With all the variations of this molecule in the human genome the challenge remains to 
understand how the kinase is able to function selectively in response to a given stimuli.
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While PKA responds specifically to levels of cAMP, there are several factors that 
give PKA diverse physiological roles. One factor is the presence of multiple C- and R- 
subunit isoforms, which can be expressed ubiquitously or with tissue- or cell-type 
selectivity (6,13). This suggests that C- and R-subunit isoforms have specific physiological 
roles. Thus, specific functions in the cell can be addressed by either expressing or 
activating specific isoforms. Functionally different PKA holoenzymes can be formed and 
localized in combinations of functionally distinct C- and R-subunit isoforms, some of which 
have been identified in vivo (5,13,94,95) and provide a potential mechanism to diversity 
and/or fine-tune cAMP signal transduction downstream of the holoenzyme. Such 
differences have been characterized between C a and C(3 as pure proteins and in the intact 
cell (95,96). Comparative studies have also been done between C a  and Cy from partially 
purified cell extract (5).
Functionally distinct PKA holoenzymes can be fine-tuned through differential 
association of the varying isoforms to form hetero- or mono-isoform composed 
holoenzymes that contain different catalytic or regulatory subunit isoforms within a given 
holoenzyme. Thus, not only do the classic Type I PKA or Type II PKA holoenzymes form 
in the cell, which contain only RI or RII isoforms, respectively, but also holoenzymes 
containing both RI and RII isoforms can form. Such holoenzymes have recently been 
observed in T-cells (97). Also, holoenzymes containing multiple C-subunit isoforms were 
observed. Thus, multiple C-subunits can be present in a given cellular location within a 
given holoenzyme allowing for multiple targets to be phosphorylated with different 
specificities in response to a single signal. Or if required, only one C-subunit and or R- 
subunit isoform could be present within the holoenzyme, allowing for only one very
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specific response to a given stimuli. What structural differences between PKA C-subunits 
would render them such functional differences that would give the cell the ability to 
mediate multiple cellular responses through the expression of different isoforms? Our 
hypothesis is that differences between C-subunits may be due to differences in their 
primary sequence, which would lead to differences in secondary and tertiary structure 
between C-subunit isoforms. This hypothesis will be tested under Specific Aim 1, in 
Chapter II, where chimeric constructs will be generated by swapping regions of low 
sequence homology between two C-subunit isoforms and tested for changes in function.
A second factor that may give PKA a diverse role in the cell is its regulation by 
other proteins. Proteins known to regulate PKA include protein kinase inhibitor (PKI), A- 
kinase anchoring proteins (AKAP), and phosphoinositide-dependent kinase-1 (PDK-1). 
The pseudosubstrate PKI inhibits and exports C a from the nucleus (98) but Cy is 
insensitive to PKI (5,13). This is due to specific differences in the amino acid sequence 
between C a to Cy (S133Q and Y235F) that form a hydrophobic pocket for PKI-binding 
(99,100). Since the R-subunits do not enter the nucleus (8 8 ), this raises the question of what 
regulates Cy gene transcription activity in the nucleus.
AKAPs represent another PKA-regulating protein (101). AKAPs bind the R- 
subunit and localize PKA holoenzymes in regions where the protein is required. This 
leaves the kinase and substrate co-localized in a relatively high concentration, increasing 
substrate specificity. As Cy has a lower affinity for R-subunits than C a  (102), Cp or PrKX 
differ in their affinities for different R-subunit isoforms (46,95), AKAP proteins may not 
regulate Cy to the same extent they regulate C a, Cp or PrKX. Furthermore, C a, Cp and
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PrKX localization may be determined through differential associations with the various R- 
subunit isoforms.
PKA is also regulated by other kinases (103). In mammalian cells a candidate is 
PDK-1, which phosphorylates C a at T197, increasing its catalytic activity (104), but it is 
not known if PDK 1 phosphorylates Cp, Cy or PrKX. It is tempting to assume that this 
mechanism is conserved across the different C-subunit isoforms as the regions required for 
PDK-1 modification of C a are conserved among all of them. But this has yet to be 
determined experimentally. In the cell PDK-1 does increase the rate of Cy-mediated 
transcription but has little effect on Ca-mediated transcription (105).
Each of the proteins just described regulate PKA, but with potentially different 
effects on the function of each. One of the most important regulation mechanisms is the 
phosphorylation of C a at T197, which increases its catalytic activity 100-fold (87). It has 
not been tested whether this modification is significant for all of the PKA C-subunits, even 
though structural similarities between them suggest it might be. Differential regulation of 
this modification among PKA C-subunit isoforms would provide the cell with another 
mechanism to fine-tune cAMP-mediated signal transduction pathways. Specific Aim 2, in 
Chapter III, will test the significance of this modification to the function of two PKA C- 
subunits.
A third factor that may give PKA diverse physiological roles is the kinetic 
mechanism of each of the catalytic subunit isoforms. Three of the four catalytic isoforms 
(Ca, Cp, and Cy) have been shown to vary in substrate specificity as determined through 
variance in their catalytic rate constants for the same physiological substrates (20,95). This 
suggests that each catalytic subunit may have ‘preferred’ physiological substrates which
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they will modify in response to a given stimuli. This selectivity may allow a given stimuli 
to elicit each catalytic subunit to modify different substrates. In addition, the kinetics of 
phosphorylation may differ between the isozymes resulting in a temporal difference of 
phosphorylation-mediated activation or inactivation mechanisms that are important to the 
sequence o f events regulated by cAMP (12). Specific Aim 3, in Chapter IV, will test if 
there is a divergence in the kinetic mechanism of two PKA C-subunits that could explain 
differences in steady-state kinetics for a given substrate.
Together these factors present a model wherein a cell can mediate different 
cellular mechanisms in response to the same physiological stimuli through differential 
expression, localization, and substrate-specificity by different isoforms of the same 
protein kinase. Characteristics of this model seem most striking when comparing two 
PKA C-subunits that have the greatest divergence in function while maintain relatively 
high structural homology, C a and Cy. These two isoforms serve as a simple model for 
structure-function characterization of kinases in order to determine what structural 
components in these two C-subunits provides them diverse functions, and how this 
translates to functional divergence in other protein kinases.
The conserved structural homology and functional divergence between C a  and 
Cylend them as an ideal model fo r  protein kinase structure-function studies- While both 
C a and Cy share 83% identity in primary structure they differ in gene transcription 
regulation and substrate and pseudosubstrate specificities (5,20,105,106). Differences in 
gene transcription regulation were observed through transient transfections in luciferase- 
reporter assays where C a induced a three to ten-fold higher activation o f CREB-response 
elements containing promoters than Cy (105). Differences in pseudosubstrate and
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substrate recognition have been observed where C a is inhibited by PKI while Cy is not 
(13,20). Another striking difference between Cy and C a is that while both share similar 
Km values (steady-state constant associated with affinity by the enzyme for a given 
substrate) for most substrates, suggesting similar affinities, they have very different Vmax 
values (steady-state measure o f the enzyme’s reaction rate for a given substrate), with Cy 
at least ten-times slower than C a (20). These differences between C a and Cy suggest that 
while both enzymes are cAMP-dependent, they may fulfill different functions within the 
cell. Unlike C a or C(3, Cy is only found in primates (45,73) and is believed to have entered 
the primate gene pool approximately 40 million years ago as a Ca-retroposon (73). Thus Cy 
is transcribed as an intronless message and has no known splice variants, as occur for C a or 
CP (58,71). Presently the literature considers Cy to be structurally and kinetically 
homologous to C a and Cp (e.g. undergoing the same post-translational modifications, such 
as myristylation and phosphorylation), when in fact very little is known about the Cy kinase. 
Thus, there is a clear need to express and characterize a homogeneous Cy enzyme. However 
identification, quantification and characterization of Cy has been a challenge due to its 
apparent low abundance in primate cells and tissues, the difficulty in readily expressing 
sufficient levels of the recombinant enzyme, and the absence of Cy-specific antibodies.
Cy is unique to the PKA catalytic subunit isozymes. The Cy mRNA has only been 
identified in human testes where it was cloned from a human testes cDNA library (45). 
PKA Cs, or Ca2, has recently been identified as a testes specific isoform, a splice variant 
of C a expressed in mature sperm (52,107), but unlike Cy this isoform is not human 
specific. Identification of Cy in other tissues has been difficult because of the high
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recent publication describes the identification of Cy in mouse pancreatic [3-cells through 
immunohisotchemistry (108). But this work was done with an antibody that is not 
selective for Cy and cross-reacts with other C-subunits (105), and since Cy is not present 
in the mouse, it is likely the antibody detected the prevalent isoforms expressed in most 
cell lines, C a. The antibody in question was also used to characterize C-subunit 
expression in rat cells, where it was reported to identify Cy (a primate specific gene) 
(109). Since Cy was originally identified in testes, a tissue with a high a concentration of 
cells undergoing differentiation, it is possible that Cy has a function in cellular 
differentiation. Furthermore, sperm undergo differentiation that involves specific 
isoforms of the PKA catalytic subunits (52). In addition, Cy is an intronless (45) gene, 
and many intronless genes play a role in cellular differentiation (110-116). This suggests 
that PKA may have novel role in cellular differentiation through a unique isoform that 
has not been described before.
The divergence between C a and Cy function lends these two isoforms as a good 
model system to study the effect structural divergence between protein kinases has on 
functional differences. Furthermore, studying structure-function differences in vitro and 
in intact cells may help further our understanding of the role and function of Cy in the 
cell. Each of the following chapters (II-IV) will coincide with each of the specific aims 
outlined in this chapter. Chapter V is the result of work I did in addition to the work 
outlined by my specific aims. This work was necessary to demonstrate that Cy was not a 
test-tube anomaly, but instead an isoform that has slipped through the cracks of the PKA 
research field, because, as described here in detail, Cy is limited in species expression,
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has proven difficult to isolate and it shares high homology with other isoforms expressed 
in the same cell models studied.
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CHAPTER II
IDENTIFY DIFFERENCES IN PRIMARY STRUCTURE BETWEEN PKA-Cy 
AND PKA-Ca THAT DEFINE THEIR PHYSIOLOGICAL FUNCTION IN
INTACT CELLS
ABSTRACT
The cAMP-dependent protein kinase (PKA) catalytic subunits C a and Cy share 
83% identity in primary structure but differ in gene transcription regulation. The C a 
structure has been well characterized, however physical characterization of Cy’s structure 
has not been forthcoming. Both C a and Cy share 8 6 % identity in their catalytic cores 
(amino acids 40-300), 57% identity in their amino terminal (a.a. 1-39) and 83% identity 
in their carboxyl terminal (a.a. 301-350). The C a  amino terminus is important to 
structure stability and the carboxyl terminus is important to substrate recognition by the 
kinase. The divergence in homology in the amino and carboxyl terminals makes these 
likely regions to be responsible for structure-function differences between C a and Cy. 
This hypothesis was tested here with chimera constructs wherein the first 50 and terminal 
70 amino acids were swapped between C a  and Cy and tested through transient 
transfections with CREB-mediated reporter assays. While both wild type (wt) isoforms, 
C a  and Cy, induced transcriptional activation, the chimera transfections failed to exhibit 
any activity in COS7 cells, but exhibited some activity in Kin8  cells. This difference in 
cell-type dependent activity may suggest that there are cell-type specific factors that are 
required for the proper expression of the chimeras. Immunoblot analysis demonstrated
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that each of the chimeras was expressed in COS7 cells and sequence analysis o f the 
constructs suggests that the expressed chimeras should have the expected primary 
sequence. While it is difficult to interpret the results obtained from the chimera studies, 
the amino and carboxyl terminals remain important regions o f divergence between C a 
and Cy that warrant further study.
INTRODUCTION
The catalytic subunits for the cAMP-dependent protein kinase (PKA) propagate 
extracellular signals through intracellular pathways by phosphorylating protein substrates 
at serine or threonine amino acids located within specific sequences (R-x-x-S/T and R-R- 
x-S/T are two common ones (1)) in response to an increase in intracellular concentrations 
of cAMP. PKA modifies substrates in the membrane, the cytosol, and the nucleus (1). 
One of the cellular functions regulated by PKA is gene expression through modification 
of transcription factors in the nucleus such as the cAMP-response element binding 
protein (CREB), the cAMP-response element modulator (CREM), and the Nuclear 
Factor-KB (NF-kB), or through modification of transcription factor regulators in the 
cytosol such as the NF-kB inhibitor (IkB) (1).
O f the four human PKA catalytic subunits (Ca, Cp, Cy and PrKX), the structure- 
function differences between C a and Cy are the most striking (5,105). Cy is a putative 
retrotranspostion of C a inserted into the human genome some 40-million years ago (73), 
which maintains 83% identity with C a in primary sequence but differs in transcriptional 
regulation through CRE-containing promoters (5,105). Differences in the transcriptional 
regulation range depend on the cell-type used, but Ca-regulated, CREB-mediated 
transcriptional activity tends to be 3-10 times greater than that o f Cy (105). There is some
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evidence that Cy may favor transcriptional activity through a different transcription 
factor, Spl (105), but this work remains to be corroborated by others. There is 
independent work demonstrating that PKA regulates Spl-mediated transcriptional 
activity measured in a human cell line (HL60 cells), however the catalytic subunit(s) 
responsible for Spl-mediated transcriptional activity were not identified (117).
As biochemical reactions in the cell follow the structure-equals-function adage, it 
is possible that differences in function between C a and Cy can be attributed to 
differences in structure. The C a structure has been well characterized through 
chrystallography, circular dichroism, and NMR analysis (33,118-120). However, physical 
characterization of Cy’s structure has not been forthcoming because its isolation in 
sufficient quantities required for this type of characterization has proven difficult (20). It 
may be possible to predict which regions of the protein confer C a  and Cy functional 
differences based on differences in their primary sequence. C a ’s sequence can be divided 
into three regions that correspond to structural domains in the folded protein. These 
include the amino terminus (amino acids 1-39), the catalytic core (amino acids 40-300), 
and the carboxyl terminus (amino acids 301-350) (118,121,122).
C a and Cy share 8 6 % identity in their catalytic core, which is conserved in most 
of the 518 protein kinases in the human genome and has been used as template to define 
this region in the protein kinase family (123). The C a amino terminus is important to the 
enzyme’s stability and its interaction with the PKA psuedusubstrates. Deletion of the first 
14 amino acids yields a functional isozyme that losses thermostability (a decrease in Tm) 
but maintains kinetics similar to wt C a  (121). Deleting the first 39 amino acids yields a 
non-functional isozyme (121). Interestingly, both isozymes increase the thermostability
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of the holoenzyme (121). C a and Cy share approximately 57% sequence identity in the 
first 40 amino acids, making this a likely region responsible for structure-function 
differences between the two isoforms. It is also possible that this region is less important 
to the overall function of the enzyme and therefore there can be more variance in the 
amino-terminus of the enzyme, with little effect to the enzymes catalytic function. Nine 
o f the first 39 amino acids are not conserved between Cy and C a  (at positions 6 , 9, 10, 
11, 12, 24, 28, 31, and 34), which constitutes 29% of the amino acids in this region, 
lending credence to the later.
The C a carboxyl terminus is important to substrate recognition by the kinase 
(122). Through alanine substitutions four o f the 49 amino acids in this region have been 
shown to be important to affinity with ATP (K317, K319, T330, and E332) and six are 
important to affinity with the phospho-acceptor substrate (1315, T330, V 337,1339, K345, 
and G346) (122). The carboxyl terminal region evidences relatively high homology in 
both isoforms (83% identity between C a  and Cy), but two residues important to C a 
affinity for ATP and Kemptide are mutated in Cy (K319T and V337I), which may be 
important to functional differences observed between the isoforms.
Here we decided to test the importance of the amino and carboxyl terminal 
regions to the function of each isoform, C a and Cy, by generating chimeras of these 
regions. It was hoped that placing either the C a  amino or carboxyl terminus on Cy would 
confer Cy Ca-like functions and that the inverse would hold true for C a. With this in 
mind, the first 50 amino acids and the terminal 70 amino acids were swapped between 
each isoform and these isozymes were then tested in transient transfections for CREB- 
mediated reporter activity through a reporter vector consisting of a a-glycoprotein
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hormone promoter (which contains two CREB response elements) upstream of a fire fly 
luciferase open reading frame. Unfortunately both the amino and the carboxyl terminal 
chimeras were expressed as non-functional proteins, exhibiting a total loss of 
transcriptional activity in COS7 cells relative to the wt isozymes. Loss of activity was not 
due to a lack of isozyme expression as was demonstrated through immunoblot analysis, 
but may be due to numerous other factors that were not tested here. An alternative to the 
approach used here would be to express the chimeras for purification and compare their 
in vitro kinase activity to that of the wild type subunits. But this approach defeats the 
purpose of measuring chimera activity through transient transfections, which was to 
avoid the complications inherent to protein purification of an active enzyme, especially 
one of limited stability such as Cy. However, transient transfection reporter assays with 
C-subunit chimeras did not address the question as to the significance of the amino and 
carboxyl regions to structure-function differences observed between C a and Cy, but that 
does not eliminate the study of these regions as a potential source for functional 
divergence between C a and Cy.
MA TERIALS AND METHODS
Tissue Culture Conditions -  Kin8  mouse adrenal cells were maintained in Hams F-10 
media with 1 0 % heat inactivated horse serum and 1 % neomycin as previously described 
(5). COS7 cells were grown in DMEM with 10% FBS. Both cell lines were maintained in 
5% C 0 2 at 37°C.
Chimera constructs- The Chimeras were gifts from Wei Qing Zhang, who constructed 
both the amino and carboxyl C a and Cy chimera expression vectors (Appendix B). 
Primers were ordered through Invitrogen. Sequencing o f chimeras was done in-house
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using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), according to 
the manufacturer’s instructions, on a 3100 Avant Genetic Analyzer (Applied 
Biosystem/Hitoch) automatic sequencer.
Plasmids-  pCMV-Ca was a gift from Dr. Michael Uhler (University of Michigan, Ann 
Arbor). The pCMV-Cy expression plasmid was created with the addition of BamHI linkers to 
the EcoRI ends of the original Cy cDNA (45) and subcloning the product into the Bgll site of 
the same pCMV expression plasmid as used for Ca. The a-glycoprotein hormone firefly 
luciferase reporter plasmid (pGHa-fluc) (124) was a gift from Dr. G. Stanley McKnight 
(University of Washington, Seattle). The pCMV-RIIa-GFP expression plasmid used to 
determine transfection efficiency was a gift from Dr. Suzan S. Taylor (University of 
California, San Diego). A pUC19 vector was used as a filler vector in all transient transfection 
experiments.
Reporter Assay Studies- Kin8  and COS7 cells were added at 325,000 cells per well in 6 -well 
plates (9.6 cm /well) (Coming Inc). Cells were allowed to grow for 24 hours to approximately 
60% confluence before transiently co-tranfecting with expression, reporter, and/or filler 
plasmids. The total amount of DNA loaded into the cell was tested in the ranges of 0.5-3.0 pg 
using FuGENE 6  (Roche Molecular Biochemicals) at a 3 pL Fugene: lpg  DNA ratio, before 
arriving at the levels described for each experiment. After 24 hours, the transfected cells were 
harvested in 500 pL/well of Cell Culture Lysis Reagent (Promega). Firefly luciferase activity 
was measured using a Luciferase Assay System (Promega). Briefly, a 100 pL of sample lysate 
was added in duplicate wells of a 96-well plate, followed by 100 pL of firefly luciferase 
substrate, luciferin, in “Luciferase Assay Buffer.” The plate was then shaken for 2 seconds and 
the number of photons released measured for 1 0  seconds using a flash assay setting on an
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MLX Microtiter Luminescence Detection system (Dynex Technologies), recorded in relative 
luminescence units.
Immunoblot Analysis -  Lysate from samples analyzed by luminometry was assayed with 
BioRad’s Protein Assay reagent to determine protein concentration. A total of 1 pg 
protein/transfection condition was loaded in duplicate on a single gel and separated on a 
4% stacking, 7.5% running SDS-PAGE gel (125), then transferred to a PVDF membrane 
using a semi-dry blotting apparatus (BioRad, according to the manufacturer’s 
instructions). The membrane was cut in half and probed with either a rabbit polyclonal 
antibody (pAb, Santa Cruz Biotechnology, catalogue # sc903, lot E088, diluted 5000- 
fold), which cross-reacts with both C a and Cy or a rabbit monoclonal antibody (BD 
Transduction Laboratories catalogue # 610980, lot 6 , diluted 1000-fold), which 
selectively recognized C a, but not Cy. Immunoblots o f chimeras were analyzed using the 
pAb to Ca. The PVDF membranes were then incubated with a goat anti-rabbit pAb or 
anti-mouse pAb conjugated with horseradish peroxidase (Amersham-Pharmacia Biotech). 
The membranes were exposed to ECL reagents (Amersham-Pharmacia Biotech) and 
imaged on film (Hyperfilm, Amersham-Pharmacia Biotech) or through digital imaging 
on a VersaDoc (BioRad).
RESULTS
Chimera Transient transfections- Transfections were carried out in both Kin 8  mouse 
adrenal cells and COS7 monkey kidney cells, because wt pCMV-Ca and Cy provide 
good reporter assay signals above background (105). COS7 cells are a good model 
system for testing Cy because this is the only primate specific catalytic subunit identified 
to date (73), and transcription co-factors that may be required to mediate Cy-regulated
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transcription are likely to be present in a primate cell line. Kin8  cells were used as a 
model because they lack any endogenous Cy, thus any differences observed in an in-cell 
reporter assay are likely to be due specifically to the ectopic expression of Cy. Transient 
transfections were carried out here using 0.1 pg expression vectors and 0.5 pg reporter 
vector, as these concentrations have previously been demonstrated to be optimal in 
reporter assay experiments (105). Under these conditions, in COS7 cells, the wt pCMV- 
C a  signal was 100-fold above background of a pUC19 empty vector, and the wt pCMV- 
Cy signal was ten-fold lower than this signal (Figure 3). This difference in C a and Cy 
reporter activity is consistent with previous experiments in COS7 cells (105). The amino 
terminal chimeras consisted o f swapping the first 50 amino acids between each C-subunit 
and the terminal 70 amino acids for the carboxyl terminal chimeras. Sequencing of the 
chimera constructs demonstrated the expected sequence, however no luciferase activity 
was measured in the COS7 cell transfections with the chimera isozymes. Higher 
concentrations were tested (0.01-3.0 pg DNA) with no apparent change in the signal 
measured (data not presented).
The difference in reporter activity between C a and Cy is not as striking in Kin8  cells. A 
higher amount o f expression vector was necessary to obtain robust signals from 
transfections in Kin8  cells (105), thus all transfections in Kin8  cells were done with 1.0 
pg expression vector. The signal measured for wild type C a was 14-fold lower in Kin8  
cells and about 5-fold lower for Cy (Figure 4), which is only a 3.5 fold difference in 
reporter activity between C a and Cy. Furthermore, unlike transfections in COS7 cells, 
transfections with amino terminal chimeras in Kin8  cells did not eliminate all
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F ig . 3. Transient transfection in COS7 cells with chimeras. Co­
transfections with wild type (wt) or chimera expression vectors and 
pGHa(CRE4) reporter vector in COS7 cells, n=3, y-axis expressed as Fold 
Lums Above Background.
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activity measured from the wt isozymes. There was about a 1.75-fold decrease from wt 
C a  with the Cy amino-terminal chimera and the Ca-amino terminal chimera activity did 
not decrease from wt Cy activity (Figure 4). It should be noted that there was not much wt 
Cy activity to begin with (2-fold above background). The carboxyl terminal chimeras 
were not tested in Kin8  cells.
Immunoblot analysis o f  chimera transfections in COS7 cells- Extracts from COS7 
transfections were analyzed by immunoblot to determine whether the lack of chimera- 
mediated activity was due to a lack of expression of the isozymes during transfection. 
Two different antibodies were used selectively to distinguish C a expression from Cy 
expression. The first was a polyclonal antibody (pAb) to the carboxyl terminus o f C a that 
cross-reacts with Cy. The second was a monoclonal antibody that is selectively 
immunogenic against the C a catalytic core and does not cross-react with Cy (105) 
(copyright permission for use of Figure 5 A in Appendix C).
Through use of these anotibodies it was demonstrated that C a and Cy proteins 
were expressed after eighteen hours (Figure 5A). The polyclonal antibody cross-reacts 
with a nonspecific band that is larger than 40 kDa and is present at similar levels in 
control cells, where no C-subunit was identified following 18 hours. As the harvest of 
transfected cells was done following a 24-hour incubation, the immunoblot demonstrated 
that this is sufficient time for the ectopic expression of each isoform. Once it was 
established that both wild-type isozymes were being expressed, the polyclonal antibody 
was used to measure the expression of the amino terminal (Figure 5B) and carboxyl
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N on-specific
F ig . 5. Immunoblot analysis of transfections in COS7 cells. A, shows 
the use of a monoclonal antibody to C a  (left panel) or a polyclonal 
antibody to C a (right panel) in immunoblots of extracts from COS7 
transfected with wt pCMV-Ca and pCMV-Cy analyzed at 0 and 18 hours 
after transfections (indicated above each lane). B, shows immunoblot of 
amino terminal chimeras treated with pAb to C a following a 24-hour 
transfection. C, shows immunoblot of carboxyl terminal chimeras treated 
with pAb to C a following a 24-hour transfection. Arrows point at the 
position o f the catalytic subunit (Cs) and the non-specific band.
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terminal chimeras (Figure 5C) and it appears that the chimera isozymes were expressed 
during the 24-hour transfection.
DISCUSSION
Protein folding and its tertiary structure are determined by the sequence o f its 
primary structure (126-129) and protein function is dependent on its structure2. Regions 
of high divergence between C a and Cy at their amino and carboxyl terminals could 
explain functional differences measured between them. Functional differences between 
C a and Cy include differential regulation of CREB-mediated transcription and 
differences in steady-state kinetics for physiological substrates. In both instances Cy- 
function is less efficient or slower than that of Ca. Differences in transcriptional 
regulation can be linked directly to differential regulation of physiological mechanisms, 
as transcriptional regulation is significant to the regulation of multiple cellular events.
Both C a and Cy are 350 amino acids long and maintain a high degree of 
homology throughout the kinase catalytic core (amino acids 40-300, 8 6 % identity) but 
they diverge significantly in primary sequence in the first 40 amino acids (57% identity) 
and less so in the terminal 50 amino acids (83% identity). Each of these three regions is 
associated with specific functions for Ca. Several approaches could be taken to study the 
effect these differences have on C a and Cy function. The approach taken here was to 
swap entire sections of each isoform, generating two new isozymes with the expectation 
that placing the Ca-terminals on Cy would make Cy function more like C a and vice 
versa. The chimeras were extended slightly beyond the amino and carboxyl terminal 
regions, the first 50 instead of 40 amino acids and the terminal 70 instead of 50 amino
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acids, in part because this was where primers for generating the chimeras would work 
best. The homology between C a and Cy does not change significantly with the added 
length exchanged between the chimeras. The sequencing o f the chimera constructs agreed 
with the expected sequence, thus, based on the sequence, no further alterations to the 
protein structure were expected in the products from the chimera expression vectors. 
While the wt C-subunit expression vectors behaved as expected in the luciferase reporter 
assays no measurable activity was detected from any o f the chimera expression vectors in 
the COS7 cells transfections. Chimera transfections in Kin8  cells did have activity, but in 
this cell line the signal of the wt isoforms was not very robust. Differences in activity 
between COS7 and Kin8  suggests that there may be cell type specific factors that modify 
transcriptional activity, but it is not clear why no activity was measured at all in COS7 
cells. Sequencing of the expression vectors and immunoblot analysis of cell lysate 
suggests that the protein was being expressed with the correct primary sequence in the 
cell. Thus, the difference in activity between Kin8  and COS7 cell transfection 
experiments may be due to factors involved in protein stability. It may be that Kin8  cells 
have better repair mechanisms for misfolded protein than do COS7 cells. If so, this would 
suggest that the reason that no activity was measured in COS7 cells was that the chimeras 
expressed as miss folded proteins and were not rescued by a mechanism to help re-fold 
them properly. However, misfolded proteins are normally found in the insoluble fraction 
of cell lysate and the immunoblot analysis of COS7 cell lysate where the ectopically 
expressed C-subunits were identified (Figure 5) were of the soluble fraction. This would 
suggest that the proteins expressed were properly folded. So while the likely explanation
2 “Structure-equals-function” was our daily chant in B iochem istry at Old D om inion U niversity as taught by  
Mark Elliott, Ph.D.
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is that Kin8  cells express factors that facilitate the function of the chimeras, the nature of 
these factors is not clear. The approach of co-expressing the chimeras with protein 
chaperons associated with helping in protein folding (reviewed in (130)) could be used to 
test this hypothesis.
It may also be possible to trace the degradation of the chimeras in the cell through 
S35-labeling the ectopic proteins and compare the half-lives o f the chimeras to the half- 
lives of wild-type isoforms when expressed in COS7 and Kin8  cells. This approach has 
been used successfully to measure the half-life of wt C a  in mouse derived cell lines (79). 
A shorter half-life for the chimera relative to wt isoforms would suggest that the chimeras 
are misfolded and being degraded more rapidly than wt isoforms in the cell (79,131). 
Another approach to determine whether the chimeras are not folded properly would be to 
isolate the protein (through immunprecipitation) and analyze the protein for structural 
differences between wild-type and chimera proteins using circular dichroism, which 
would show changes in secondary structure that could be associated with protein 
misfolding (119,132-134).
In retrospect, it is possible that the approach utilized here was not the best one to 
address structural differences that attribute C a and Cy functional differences in the cell. 
A better approach might have been to generate select point mutations throughout the 
regions of interest (the amino and carboxyl domains) that would make one isoform 
resemble the other more closely. There are 17 amino acids that are not conserved in the 
Cy amino terminus. Each of these amino acids could be mutated to generate 17 
independent isozymes for each isoform. Two more isozymes could be generated, one of 
C a  and one of Cy, each containing all 17 of the mutations. While this approach may not
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work, the modifications made here to each wt Cs isoform in generating the chimeras were 
dramatic and the single point mutant approach may allow for the characterization of the 
effect each difference has on the overall enzyme structure and function. A similar 
approach has been used to study the C a carboxyl domain, where each amino acid of 
interest was mutated to an alanine and each isozyme characterized for function and 
stability (122). This approach provided some insight into which amino acids in the 
carboxyl group were important to Ca-function. The C-subunit amino terminus still 
remains a region o f interest that should be investigated further. This region evidences the 
highest divergence in homology and is important to overall protein and holoenzyme 
stability.
One problem with characterizing purified recombinant Cy is that it lacks the same 
stability as C a  (20, 135), so another explanation for differences in function between C a 
and Cy may be that Cy is less stable in the cell and therefore less abundant. Differences in 
amino-terminal region may also confer on Cy a different tertiary structure than that of 
C a. Until studies are done comparing this domain in C a and Cy, it will remain unclear 
what effect differences in these regions have on differences in function between isoforms.
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CHAPTER III
CHARACTERIZATION OF PROTEIN KINASE A CATALYTIC SUBUNITS a
AND y PHOSPHORYLATION
ABSTRACT
O f the four human catalytic subunit isoforms- C a, C[l, Cy and PrKX- C a  has 
been studied extensively and serves as model for all protein kinases but very little is 
known about Cy, the only primate specific PKA catalytic subunit. While both Cy and C a 
share 83% identity in primary structure, they differ in steady-state kinetics. A striking 
kinetic difference between Cy and C a is that, while both share similar Km values for most 
substrates, suggesting similar affinities, they have very different Vmax values, with Cy at 
least ten times slower than C a. One explanation for the difference observed in their Vmax 
is that Cy and C a  are not phosphorylated to the same extent. Phosphorylation at T 197 is 
key to C a steady-state kinetics, and increases its catalytic rate 100-fold. Experimental 
evidence suggests that Cy is either not phosphorylated, or not phosphorylated to the same 
extent as C a at conserved residues S139, T197 or S338. Differences in phosphorylation 
between C a and Cy were studied here through reporter assays using Cy and C a T197 
point mutants, immunoblot analysis using an anti-phospho T197 selective antibody and 
LC-MS/MS phosphomapping of purified recombinant proteins. Two novel 
phosphorylation sites were identified on both isoforms by LC-MS/MS analysis (Cy pS14
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and C a and Cy pS259). It was also determined that Cy is phosphorylated homologously 
to mammalian expressed C a (pT197 and pS338) and the modification at T197 is 
important to the function of both isoforms, suggesting that differences in post- 
translational modification are not the reason for kinetic differences observed between 
these two isoforms.
INTRODUCTION
In the human genome 518 kinases are known to exist (2), but few have been 
studied as extensively as cAMP-dependent protein kinase (PKA). In the absence of 
cAMP, PKA exists as a tetrameric holoenzyme composed of a regulatory subunit dimer 
and two catalytic subunit monomers. The regulatory subunits bind cAMP inducing the 
release of the catalytic subunits from the holoenzyme. Once released, the catalytic 
subunits are active and able to phosphorylate multiple substrates, propagating 
intracellular signals that regulate multiple cellular events (1). O f the four human catalytic 
subunit isoforms- C a, Cp, Cy (45) and PrKX (46) -C a  has been studied extensively and 
serves as a model for all protein kinases (23) but very little is known about Cy, the only 
primate specific PKA catalytic subunit (45). While both Cy and C a share 83% identity in 
primary structure (Figure 6 ), they differ in chromosomal location, gene structure, gene 
transcription regulation, kinetics, and specificity for peptide substrates and 
pseudosubstrates (5,20,105,106). A striking kinetic difference between Cy and C a is that 
while the two share similar Km values for most substrates, suggesting similar affinities, 
they have very different Vmax values, with Cy at least ten times slower than C a  (20).
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F ig . 6 . Sequence alignment of cAMP-dependent protein kinase catalytic 
subunits, C a and Cy. Mus musculus C a and Homo sapiens Cy. Both enzymes share 
81% identity in primary amino acid sequence (shaded) with a 58% identity at the 
amino-terminus (residues 1-40), 83% identity at the carboxyl-terminus (residues 280- 
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serine 338.
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One explanation for the difference observed in their Vmax is that Cy and C a undergo 
different post-translational modifications. C a undergoes several post-translational 
modifications, which include myristoylation at glycine 1 (136), deamidation at asparagine 
2 (137), and phosphorylation at serines 10, 139, 338 and threonine 197 (82).deamidation 
and myristoylation at the amino terminus help stabilize C a (83,119), and phosphorylation 
at T197 is key to C a steady-state kinetics (87), increasing the phosphoryl transfer rate 
between ATP and the phospho-acceptor 100-fold (138). Experimental evidence suggests 
that Cy is either not phosphorylated, or not phosphorylated to the same extent as Ca. 
Specifically, while both isoforms are approximately 40 kDa, Cy has a smaller Stoke’s 
radius than C a and has slower kinetics than C a (20), both o f which agree with 
differences observed between phosphorylated and unphosphorylated C a (87,139,140).
Differences in phosphorylation between C a and Cy were tested here using a 
CREB-mediated luciferase reporter assay with Cy and C a T197 point mutants, through 
immunoblot analysis using an anti-phospho T197 selective antibody, and through 
phosphomapping of purified recombinant hisio-Ca and hi6-Cy with liquid 
chromatography coupled to tandem mass spectrometry. We found that recombinant Cy is 
phosphorylated homologously to mammalian expressed C a, which is phosphorylated at 
T197 and S338 (141) and that the modification at T197 is important to the function of 
both isoforms suggesting that differences in post-translational modification are not the 
reason for kinetic differences observed between these two isoforms.
MA TERIALS AND METHODS
Tissue Culture-  All mammalian cells were maintained in 5% CO2 at 37°C. COS7 cells 
were grown in DMEM with 10% FBS and 2 mM L-glutamine. Sf9 insect cells were
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maintained in a spinner flask (BELLCO Glass Inc.) in serum-free ExCell 420 media at 
27°C.
Plasmids- pCMV-Ca was a gift from Dr. Michael Uhler (University o f Michigan, Ann 
Arbor). The pCMV-Cy expression plasmid was created with the addition of BamHI 
linkers to EcoRI ends of the original Cy cDNA (45) by subcloning it into the Bgll site of 
the same pCMV expression plasmid as used for Ca. The a-glycoprotein hormone firefly 
luciferase reporter plasmid (pGHa-fluc) (124) was a gift from Dr. G. Stanley McKnight 
(University of Washington, Seattle). The pCMV-RIIa-GFP expression plasmid used to 
determine transfection efficiency was a gift from Dr. Suzan S. Taylor (University of 
California, San Diego). A pUC19 vector was used as a filler vector in all transient 
transfection experiments. The pET16b-hislO-Ca was generated by Sean Collins and was 
a gift from Dr. Michael Uhler. Homologous recombination to produce pVL1393-his6-Cy 
baculovirus was done as described elsewhere (2 0 ).
Protein Expression and Purification- Recombinant murine hisjo-Ca was expressed from 
a pET16b expression vector from IPTG (0.40 mM final) induced BL21(DE3)pLysS 
(Novagen) transformed competent cells grown overnight in the presence of ampicillin 
(50pg/mL) at 37°C. For 1L of transformed cells (~3g cells), cell suspension was 
centrifuged at 11, 500 g (JA14 rotor, Beckman J2-MI), at 4°C, for 2h. The supernatant 
was discarded and the cell pellet stored at -80°C. Cells were harvested in 20 mL binding 
buffer (50 mM NaPCL, pH [7.9], 0.5 M NaCl, 10% glycerol) with 2 mM PMSF. The cell 
suspension was sonicated 5 x 6  sec (mid-setting on a 550 Sonic Dismembrator, Fisher 
Scientific), while on ice, with 1 min between sonications. Extract was loaded onto a pre­
equilibrated 7 mL Ni-IMAC column (ProBond, Invitrogen) and washed with 10 CV wash
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buffer (binding buffer with 60 mM imidazole). Initially the enzyme was eluted with an 80 
mL 0.06-1.0 mM imidazole gradient in binding buffer, while collecting 1 mL fractions, 
with the elution peak at about 350 mM imidazole, followed by separation on a Sephadex 
S300 gel filtration column. It was subsequently found that similar results were obtained if 
the protein was eluted with a 20 mL 0.06-1.0 mM imidazole gradient off a 2 mL Ni- 
IMAC column, while forgoing the gel filtration step (while loading the same amount of 
cell lysate). Both approaches provided about 5.5 U/mg of pure hisio-Ca. 
Unphosphorylated hisio-Ca was obtained by expressing pET16b in BL21(DE3)pLysS 
cells in the presence of membrane permeable, Ca-ATP inhibitor H89 (100 pM final, 10 
mM stock in DMSO) and purified through Ni-IMAC chromatography.
For protein expression and purification of human his6-Cy, Sf9 cells were grown to 
70% confluence in spinner flasks (approximately 2 xlO6 cells/mL in 1L of growth 
media), infected with his6-Cy-baculovirus (80 pfu/cell) and incubated for three days at 
27°C. Infected Sf9 cells were centrifuged (1,500 x g for 5 min) and the pellets stored at - 
80°C as 500 xlO6 cell/aliquots. Aliquots were homogenized in 15 mL binding buffer (50 
mM K P04, pH [7.9], 250 mM KC1) with 2 mM PMSF using a ground glass dounce 
homogenizer (Pyrex). The homogenate was centrifuged (15,800 x g for 30 min at 4°C) 
and the supernatant was applied to a 15 mL Ni-IMAC column (=3xl07 cells/ml resin). 
The column was washed with 3 CV of binding buffer, 10 CV of wash buffer (binding 
buffer with 60 mM imidazole) and eluted with an 80 mL 60-600 mM imidazole gradient 
in elution buffer (binding buffer adjusted to pH [6.4]), while collecting 1 mL fractions. 
Fractions were assayed for kinase activity. Fractions exhibiting the highest specific 
activity were pooled and concentrated with Amicon Ultra-15 Centrifugal Filter Devices
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(Millipore, 10, 000 MWCO). The protein peak elution occurred at ~ 350 mM imidazole. 
The purified protein had a SA of 0.5 U/mg and was analyzed for purity by SDS-PAGE 
subjected to silver staining, coomassie staining, or Sypro Ruby Staining (Molecular 
Probes).
Point M utants- Site-directed point mutants T197D and T197A were incorporated directly 
into pCMV-Ca and pCMV-Cy expression vectors using QuickChange II XL site directed 
mutagenesis kit, according to the manufacturer’s instructions (Stratagene). Primer 
sequences used for point mutants are shown in Table I. Sequencing of point mutants was 
done using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), 
according to the manufacturer’s instructions, on a 3100 Avant Genetic Analyzer (Applied 
Biosystem/Hitoch) automatic sequencer.
Reporter Assay Studies- COS7 and Sf9 cells were added at 325,000 cells per well in 6 - 
well plates (9.6 cm2/well) (Coming Inc). Cells were allowed to grow for 24 hours to 
approximately 60% confluence before transiently co-transfecting with expression, 
accessory, reporter, and/or filler plasmids (0.5-3.0 pg total DNA range) with FuGENE 6  
(Roche Molecular Biochemicals) using a 3 pL Fugene: 1 pg DNA ratio. After 24 hours, 
the transfected cells were harvested in 500 pL/well of Cell Culture Lysis Reagent 
(Promega). Firefly luciferase activity was measured using a Luciferase Assay System 
(Promega). Briefly, 100 pL of sample lysate was added in duplicate wells o f a 96-well 
plate, followed by 100 pL of firefly luciferase substrate, luciferin, in “Luciferase Assay 
Buffer.” The plate was then shaken for 2 seconds and the number of photons released 
measured for 1 0
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T a b l e  I
Primer Sequences used fo r  Point Mutants
Mutant Forward Reverse
GGGCCGCACTTGGGACT GGTCCCGCACAAGTCC
CyT197D TGTGCGGGACC CAAGTGCGGCCC
GCCGCACTTGGGCCTTGT TCCCGCACAAGGCCCA
CyT197A GCGGGA AGTGCGGC
AA AGGCCGT ACTTGGGA GGGGTCCCACACAAGT
CaT197D CTTGTGTGGGACCCC CCC AAGT ACGGCCTTT
GGCCGTACTTGGGCCTTG GTCCCACACAAGGCCC
CaT197A TGTGGGAC AAGTACGGCC
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seconds using a flash assay setting on an MLX Microtiter Luminescence Detection 
system (Dynex Technologies) and recorded in relative luminescence units. To determine 
transfection efficiency control, cells were co-transfected with 0.5 pg pCMV-RIIa-GFP, 
incubated 24 h, trypsin treated, and mounted on a slide (centrifuged at 7.06 g, 7 min on a 
Shandon Cytospin III centrifuge). Transfection efficiency was determined as a percent by 
the ratio of fluorescent cells counted under fluorescent light over total cells counted under 
white light in the same field (xlOOO magnification, under oil emersion, on a Ziess 
Axioscope fluorescent microscope). A minimum of 200 cells/transfection experiment 
were counted.
Immunoblots- Samples were separated in a 9% SDS-PAGE gels with a 4% stacking gel, 
transferred and treated with antibodies as described previously (105). Three different 
antibodies were used: a rabbit polyclonal antibody to C a, which detects both C a  and Cy 
(Santa Cruz Biotechnology sc-903, 1:1000); a rabbit monoclonal antibody to phospho- 
T197, which was a gift from Dr. Alexandra Newton’s laboratory at the University of 
California at San Diego (p500 antibody, 1:1000, generated by Dr. Joanne Johnson 
(142,143)); and a rabbit polyclonal antibody to PICA substrate phospho-serine\threonine 
(Cell Signaling, cat # 9621, 1:1000). Following primary antibody treatment and washes, 
the membranes were incubated with HRP-conjugated anti-mouse or anti-rabbit 
polyclonal antibodies (Amersham Biosciences, 1:1000), then washed. The membranes 
were developed using Immun-Star HRP substrate (BioRad) and imaged electronically 
(BioRad’s VersaDoc imaging system).
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Sf9 cells were harvested to determine PDK1 expression (10 mM potassium 
phosphate pH [6.9], 1 mM EDT, 0.5% triton-X 100 and 2 mM PMSF). PDK1 expression 
was measured with a rabbit polyclonal antibody (Cell Signaling cat # 3062, 1:1000). 
Kinase assay- In a standard kinase assay, the activity o f the C-subunits was determined 
by the transfer of y-32'P-ATP (200 pM) to peptide (65 pM Kemptide, LRRASLG) in the 
presence and absence of the protein kinase inhibitor peptide (amino acids 5-24) PKI5-24 (2 
pM), as previously described (5). Briefly, a 50 pL reaction mixture contained 30 pL test 
mix (50 mM Tris-HCl (pH 7.0), 200 pM ATP, 20 mM magnesium acetate, 10 mM DTT, 
and y32P-ATP (300 cpm/pmol)) plus 10 pL substrate. The reactions was initiated with the 
addition of 10 pL of the enzyme and incubated at 30°C for ten minutes, spotted on P-81 
paper, and placed in 75 mM phosphoric acid to terminate the reaction. The strips were 
washed in phosphoric acid 4-5 times, for ten minutes each wash, washed once in ethanol 
and allowed to dry before being placed in liquid scintillant. Specific activity 
measurements were incubated for 2, 4, 6 , 8 , and 10 minutes.
To measure phosphorylation of Cy by a PKA kinase, 128 nmoles his6-Cy were co­
incubated with 0.01 U his-PDKl (Upstate) in a standard kinase assay using kemptide as a 
Cy-substrate. Cy activity was measured at regular intervals over a 30-minute time course. 
PDK1 activity was determined in a separate experiment using PDKtide 
(KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC, Upstate) as a substrate in 
a standard kinase assay.
Phosphopeptide mapping and analysis- Protein bands were excised from polyacrylamide 
gels. Gel slices were cut into 1-2 mm cubes, washed 3 X 500 pL Ultra-pure H2O, and 
incubated in 100% acetonitrile for 45 minutes. If the gel was silver stained, the stain was
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removed with SilverQuest™ destaining solution following the manufacturer’s 
instructions. The material was dried in a speed-vac and rehydrated in 12.5 ng/pL 
modified sequencing grade trypsin solution (Promega) and incubated in an ice bath for 
approximately 45 minutes. Excess trypsin was removed and replaced with 40 -  50 pL of 
50 mM ammonium bicarbonate, pH 8.0. Proteins in solution were digested using the 
ProteoExtract™ Trypsin digest kit (Calbiochem) following the manufacturer’s 
instructions, with the exception that Promega trypsin was used instead of the trypsin 
provided with the kit. All trypsin digests were allowed to proceed overnight at 37°C. 
Peptides were then extracted 2X with 25 pL 50% acetonitrile, 5% formic acid, then dried 
in a speed-vac, and resuspended in 20 pL Buffer A (5% Acetonitrile, 0.1% Formic Acid, 
0.005% heptafluorobutyric acid (HFBA)). Digests (3-6 pL) were loaded onto a 12-cm X 
0.075 mm fused silica capillary column packed with 5 pM diameter Magic™ C-18 beads 
(The Nest Group, Southboro, MA) using a N2 (g) pressure vessel at 1100 psi. Peptides 
were eluted by applying a 55 or 150 minute, 0 -  80% linear gradient o f Buffer B (95% 
Acetonitrile, 0.1% Formic Acid, and 0.005% HFBA) at a flow rate of 130 pL/min with a 
pre-column flow splitter, resulting in a final flow rate o f -200 nL/min directly into the 
source. The LCQ-DecaXP (Thermofinnigan) was run in automatic collection mode with 
an instrument method composed of a single segment and four data-dependent, scanned 
events with a full MS scan, followed by 3 MS/MS scans of the highest intensity ions. 
Normalized collision energy was set at 30, activation Q was 0.250, with the minimum 
full scan signal intensity set at 5 X 105 and a minimum MS2 intensity at 1 X 104. 
Dynamic exclusion was turned on utilizing a three-minute repeat count o f 2, with the 
mass width set at 1.50 Da. Sequence analysis was performed with Sequest™ using an
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indexed human subset database of the non-redundant protein database from NCBI (PKA- 
Cy accession number: NM_002732, PKA-Ca accession number: NP_032880).
Protein Phosphatase Treatment- Samples containing 50 pmol (2 pg) pure hisio-Ca were 
incubated with 0.75 U of bovine kidney PP2Ai (0.5 pg, >90% pure, Sigma) in 50 pL 
reaction buffer (20 mM Tris-HCL, pH [7.5], 2 mM MgCE, and 1 mM DTT) at 37°C for 
30 minutes. The reaction was quenched with 20% Trifluoroacetic acid. Spin-Out™ GT- 
600 desalting columns were used to replace the reaction sample buffer with 50 mM 
Ammonium Bicarbonate, pH [8.0]. Samples were digested as described above.
RESULTS
Effect o f  Point Mutants on the C-subunit’s function- It has previously been shown that 
COS7 cells are optimal for comparing C a and Cy-mediated reporter activity through 
CRE-containing promoters, such as the a-glycoportein promoter (105). Sf9 cells were 
also used as a model because they are the same cell line from which recombinant Cy is 
purified (20). Dose response studies with 0.5 pg pGfta-fluc and 0.01-1.0 pg pCMV-Ca 
wt and pCMV-Ca T197D determined that 0.1 pg and 1.0 pg were the most effective 
doses for transfections with Fugene6 in COS7 and Sf9 cells, respectively (data not 
shown) with a transfection efficiency of 22 ± 5 % (average ± standard deviation) 
(Appendix D). Ectopic expression of pCMV-Ca wt provides a robust signal through the 
pG H a-flue reporter vector (78-fold above background) in COS7 cells and a weaker 
signal in Sf9 cells (3.5-fold above background) (Figure 7). The C a T197A point mutation 
knocks out 98% of pCMV-Ca wt mediated reporter activity (3-fold above background) in 
COS7 cells and 25% of activity in Sf9 cells. Some 13% of pCM V-Ca wt activity is 
restored with the C a  T197D point mutant in COS7 cells and 10% activity is restored by
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this mutant in Sf9 cells. As previously reported (105), ectopic expression of pCMV-Cy wt 
mediated pG H a:/7woactivity was about 52% and 33% lower than that o f pCMV-Ca wt 
in COS7 and Sf9 cells respectively (37-fold and 2-fold above background respectively). 
However similar trends were observed with the pCMV-Cy point mutants, with Cy T197A 
mutant knocking out all activity and T197D restored activity back to pCMV-Cy wt levels 
in both COS7 and Sf9 cells. Although not shown here, cell density affected Cy-mediated 
reporter activity, where at high cell density levels(>80% confluence) little or no reporter 
activity was measured in the presence of Cy in both cell lines tested here. This 
observation did not hold true for C a transfections.
Effect o f  PKA Kinase on Recombinant Cy- C a  is phosphorylated at T197 through 
autophosphorylation in prokaryotic cells (140,144) and through another kinase in S49 
mouse lymphoma cells (103). Studies done in the intact cell and in vitro suggest that 
phosphoinositide-dependent kinase-1 (PDK1) is a candidate for physiological regulation 
of PKA (86,104,145). As recombinant Cy is expressed in and purified from a eukaryotic 
cell line (Sf9 cells) it is possible that Cy has low activity because this cell line lacks a 
PDK1 homologue to phosphorylate Cy and Cy may not be able to autophosphorylate. To 
determine whether Sf9 cells expressed PDK1, Sf9 cell extract was tested through 
immunoblot analysis using a polyclonal antibody to PDK1 (Figure 8). The antibody 
detected a band doublet of which the major band had an apparent MW of 63 kDa (as 
determined through extrapolation of its R/) that coincides with the MW reported for 
PDK1 (146,147). The band doublet may represent two different PDK1 isoforms 
expressed in this cell line or two different modification states o f the same isoform.
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F ig . 7 . T197 point mutant transient transfections demonstrate its 
importance to ca and cy function. Co-transfection of pG H a-flue with pCMV- 
Cs wt, pCMV-Cs T197D and pCMV-Cs T197A in A, Sf9 cells and B, COS7 
cells using 0.1 pg or 1.0 pg expression vector, respectively. Values are expressed 
as fold above background (transfections with pUC19).
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F ig . 8 . Immunoblot analysis of Sf9 cell extract identifies an 
immunoreactive band. Pure recombinant his6-PDKl (40 ng of truncated 
PDKI52-556, at left), Sf9 cell extract (5.8-174 jag, upper panel) and 
GAPDH (loading control) were run on a 9% gel and analyzed with an 
anti-PDKl rabbit polyclonal antibody. The apparent molecular weights 
of each band are indicated by the arrows to the right of the gel.
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Purified PDK1 was co-incubated with recombinant Cy in a standard kinase assay to test 
whether PDK1 could modify Cy activity (Figure 9A). It was found that Cy steady-state 
activity did not change in the presence of PDK1 suggesting that purified recombinant Cy 
is already phosphorylated at T197. PDK1 activity was tested independently with a PKB 
based peptide substrate, PDKtide, and Kemptide and demonstrated to be active and to 
have about three fold higher activity with PDKtide (Figure 9B).
Measurement Phosphorylation through Immunoblot Analysis- Immunoblot analysis of 
both purified isoforms was used to directly measure C-subunit phosphate content. 
Phosphate content was tested through the use o f two antibodies, one that specifically 
detects phosphorylation at T197 (142,143) and a second antibody that detects 
phosphorylation at arginine-directed serines or threonines (R-directed Ab), such as the 
PKA phosphorylation consensus sequences (R-x-x-S/T). Figure 10 shows that both 
antibodies detect phosphorylation in both pure Ca  and Cy, and C a expressed in the 
presence of H89, a membrane permeable inhibitor that selectively binds the C-subunit 
ATP binding site, was not phosphorylated. The absence of phosphate on Ca(H89) 
supports the mechanism o f autophosphorylation for E. coli expressed Ca. Both 
antibodies detect phosphorylation at T197, but the R-directed Ab may also detect 
phosphorylation at the other sites on both isoforms. C a expressed in E. coli is reported to 
be phosphorylated at four residues, S10, S139, T197 and S338 (140), but phosphorylation 
o f Cy has not previously been studied.
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F ig . 10. Immunoblot analysis of pure C a and Cy identifies both isoforms 
as phosphoproteins. Pure C a expressed ± H89 and Cy were analyzed with A, 
anti-Ca rabbit polyclonal antibody, B, anti-RxxpS/T antibody, or C, p500 
antibody, which is specific for phosphorylation at T197.
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LC-MS Phosphomapping o f  the Catalytic Subunits- Both recombinant isoforms were 
subject to LC-MS/MS analysis to identify which residues were phosphorylated. Criteria 
for considering a peptide to be phosphorylated included identification by MS/MS of 
known phosphorylation sites on C a, identified peptides must have >70% of the b or y 
ions series, the phosphorylated peptide must have been seen in at least two independent 
runs, and the total number of ions present for a given scan need to be low enough such 
that the probability of randomly assigning ion masses is statistically negligible. Three 
forms o f C a were analyzed: (1) native C a, (2) C a treated with PP2A and (3) C a 
expressed in the presence of H89, a C a competitive inhibitor that binds the Ca-ATP 
binding site and blocks Ca-autorphosphoryation when C a is expressed in its presence. 
What was expected in this experiment was the identification and then subsequent removal 
o f phosphates from Ca.
Three phosphopeptides were identified on recombinant C a  by MS/MS base peak 
neutral loss analysis (Figure 11). The phosphorylation position on the peptide was 
identified by manual spectral analysis at KgGpSEQESVKEFLAK2i (790.9 m/z) for S10 
(49 m/z loss), I 135GRFPSEPHAR144 (1170.32 m/z) for S139 (98 m/z loss), and 
G 193RTWPTLC199 (894.04 m/z) for T197 (98 m/z loss) (Figure 11). Incubating C a with 
PP2A resulted in phosphate removal only at S139 (Figure 11B) and Ca(H89) lacked 
phosphates at all three sites (Figure 11C). Base peak neutral loss chromatograms were 
normalized (NL) to base peak amplitude and a decrease in signal was observed between 
conditions (C a wt NL = 1.21 x 109, Ca(PP2A) = 8.1 x 108, Ca(H89) = 7.66 x 105).
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There may have been removal of phosphate at T197, however our approach was not 
quantitative, thus we could only measure the presence or absence of a phosphate. 
Subsequent scans using a longer gradient (150 min 0-80% buffer B) identified phosphates 
at V337PSINEKCGKEFTEF350 (1711.8 m/z, Xcorr= 1.8, ACn= 0.5) for S338 and at 
F257PpSHFSSDLK266 (1245.3 m/z, Xcorr= 1.9, ACn= 0.2) for S259.
Mapping of Cy identified phosphopeptides at four distinct sites:
D8TEQEEpSVNEFLAK2 1 (820.41 m/z) for S14 (Figure 12), 
Ti95WpTLCGTPEYLAPEIILSK2i3 (1144.309 m/z) for T197 (Figure 13), 
F257PpSKLSSDLK266 (601.86 m/z) for S259 (Figure 14), and 
Y3l6TGPGDASNFDDYEEEELRIpSINEK342 (1487.069 m/z) for S338 (Figure 15). 
Phosphorylation at Cy SI 39 was not identified in any of the LC-MS/MS runs performed. 
However, identification of phosphorylation at S259 on both isoforms is a new 
observation. Phosphorylation at C a S14 was not identified in any of the runs. 
DISCUSSION
Autophosphorylation is an important mechanism for regulating protein kinases (81). 
Escherichia coli expressed PKA-Ca autophosphorylates at four residues, S10, S I39, 
T197, and S338 (140) which are phosphatase resistant (141,144). Eukaryotic expressed 
C a  is phosphorylated at T197 and S338 by a PKA kinase (148) o f which pT197 can be 
removed by a PP2A-like phosphatase in S49 cells (148). However, phosphatase removal 
of pT197 is enhanced under denaturing (148) and oxidation conditions (149), suggesting 
that this is a very stable modification. Analysis of the Cy Stoke’s radius, in gel apparent
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F ig . 14. LC-MS/MS scan of phosphopeptide F257PPSKLSSDLK266 from 
recombinant PKA-Cy trypsin digest. Parent ion for phosphorylation at Cy 
259. m/z 601.86 12+1.
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F ig . 15. LC-MS/MS scan of phosphopeptide 
Y3i6TGPGDASNFDDYEEEELRIpSINEK342 from recombinant PKA-Cy 
trypsin digest. Parent ion for phosphorylation at Cy S338, m/z 1487.069 (2+).
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molecular weight and steady-state kinetics suggest that unlike C a, Cy may not be 
phosphorylated (20).
Characterization of PKA phosphorylation had previously been done through 
tryptic digest-analysis of P32-labeled enzyme, mass spectroscopy, analytic isoelectric 
focusing and chromatography analysis (139). Only recently has liquid chromatography 
coupled to tandem mass spectroscopy (LC-MS/MS) technology been successfully used to 
identify phosphorylation sites on recombinant C a  (150), but such characterization had 
not been tried with Cy in part because its expression and isolation has been a challenge 
(20). Recombinant Cy expresses as an insoluble protein in E. coli, but can be expressed in 
eukaryotic cells including murine Kin8 cells (5) and insect Sf9 cells (20). Both 
expression systems provide a low yields relative to C a expressed from E. coli, and once 
pure the Cy half-life at -80°C or in liquid nitrogen is much shorter than that of C a 
(months vs. years at -80°C). Recombinant his-Cy has been expressed here to ease its 
purification and characterization. This approach allowed for sufficient Cy to be purified 
for its characterization through immunoblot and LC-MS/MS analysis.
Two o f the four C a putative phosphorylation sites, T197 and S338, were 
identified on Cy via LC-MS/MS and immunoblot analysis, while phosphorylation at all 
four putative sites was identified on Ca. Two novel modifications were also identified on 
Cy at S14 and at S259 on both isoforms. The modification at Cy S14 may be analogous to 
phosphorylation at C a  S10, which is not conserved in Cy (Figure 6). The sequence 
surrounding Cy S14 (QEESV) does not fit a PKA phosphorylation site but was identified 
as a potential casein kinase 2 (CK2) phosphorylation sequence (OMIGA software). Since 
Sf9 cells contain a CK2 homolog (151) this modification may be an artifact of expressing
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Cy in Sf9 cells. However, CK2 is present in all eukaryotes, so it is also possible that 
phosphorylation at this residue is important to Cy function and that this modification is 
present on Cy expressed in human tissue and Cy ectopically expressed in murine Kin8 
cells. The function of phosphorylation at C a S10 is still not clear (119) therefore it is 
difficult to speculate what difference phosphorylation at S14 instead o f at S10 will have 
on the enzyme’s function. Phosphorylation at S259, which was observed on both C a and 
Cy, may also be an artifact of overexpressing a recombinant protein and may not have 
any biological relevance. Such is the case for modifications on C a  S10 and S I39, which 
are only observed on C a expressed in bacteria, yet have no known biological function. 
Since this modification has not been previously described for C a it may not be that C a is 
not abundantly modified at S259 and thus the modification is only present on a small 
fraction of the enzyme purified and thus not detected until now. There are at least three 
major isozymes of recombinant C a identified from E. coli expression that are distinct in 
the number of phosphates each contains (2, 3, and 4) (139), but there is some evidence 
that suggests the presence of more (personal communication from Drs. Suzan Taylor and 
Mike Deal).
The fact that both isoforms purified from different expression systems contain this 
modification suggests that the mechanism for phosphorylation at S259 may be the same 
on both enzymes. The sequence surrounding S259 (RFPS) agrees with a PKA 
phosphorylation sequence (R/KxxS/T (1)) but was also identified as a PKC 
phosphorylation site (OMIGA software). Since the modification occurred in both 
prokaryotic and eukaryotic cells it likely that phosphorylation occurred through an
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autphosphorylation mechanism for which there is a precedent in E. coli expressed C a 
(140,144,152).
Modifications to S10 and S I39 were not identified on Cy. Myristylated C a 
exhibits reduced phosphorylation at S10 and S I39 (82), however it remains to be 
determined if Sf9 expressed Cy is myristylated. Identification o f phosphorylation to C a 
S139 has been problematic for others (150) yet C a pS139 was one of the first 
modifications identified here. This discrepancy may stem from differences in expression 
conditions which may lead to differences in the phosphate content in the isozymes 
expressed (153). Phosphorylated C a S139 was identified here by base peak neutral loss 
analysis and found to be the only phosphate completely removed by PP2A, suggesting it 
is a very labile modification relative to phosphorylation at T197. Phospho-T197 may 
have only been partially removed by PP2A and therefore not observed by LC-MS/MS 
analysis.
Sf9 expressed Cy contains phosphorylation modifications analogous to 
mammalian expressed C a (141). The mechanism for phosphorylation o f Cy is not known 
at this time, but it may be through PDK1, a known PKA kinase (86,104,145). Since C a is 
a PDK1 substrate in eukaryotic systems and both C a and Cy share sequence homology at 
three o f the four putative phosphorylation sites (Figure 6) and Cy contains the PDK1- 
interacting fragment (F-x-x-F), located at the C terminus of the PDK1 substrate (154), it 
is likely that Cy also serves as a PDK1 substrate. An immuno-reactive 63 kDa band was 
identified in Sf9 cells suggesting PDK1 is present in this cell line making PDK1 
phosphorylation of Cy T197 a likely mechanism. Phosphates on C a  are very stable as 
they are not easily added or removed once the kinase is translated (139,140,144) which
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may explain why co-incubation of PDK1 did not increase Cy steady-state kinetics. Since 
Sf9 cells express endogenous C a it is also possible that C a phosphorylates Cy. Bacterial 
expressed Cy, like C a (T197A), is insoluble and inactive (20,87) so it was thought that 
co-expression of C a and Cy may increase Cy stability, however this was tested and found 
not to be true (data not shown), suggesting that either E. coli expressed Cy is already 
phosphorylated or that C a cannot modify Cy.
The use of point mutants here demonstrated that phophorylation at T197 is
important to Cy function. The T197A point mutant makes the site inaccessible to
modification and is deleterious to C a and Cy mediated transcriptional activation while 
the T197D mutation, which mimics phosphorylation at this site, restores some (Ca) or all 
(Cy) of the lost activity. Cell-type differences were observed in the amplitude o f the 
reporter signal measured between COS7 and Sf9 cells for C a  and Cy transient 
transfections. In both cell lines Cy-mediated reporter activity was lower than that o f Ca 
as has been reported elsewhere (105) but Cy-mediated reporter activity was higher in 
COS7 cells than in Sf9 cells. This difference may be due to differences in the cellular 
protein profile and in the regulation o f the C-subunit isoform. While Cy expressed from 
Sf9 cells is phosphorylated at T197, it may be that modification o f the catalytic subunits 
is more efficient in mammalian COS7 cells than in insect Sf9 cells or that Sf9 cells have 
efficient phosphatases not present in COS7 cells.
While recombinant Cy is phosphorylated at T197 and this modification is
important to the isoforms function the question still remains as to what causes the
functional differences observed between C a and Cy. Another possibility is that sequence
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differences in the C a and Cy amino and carboxyl termini (Figure 6) contribute to 
functional differences measured between them. Studies done with C a  and Cy amino and 
carboxyl terminal chimers resulted in the expression of non-functional isozymes in COS7 
cells. However, the amino terminal chimers had little effect on their function when 
expressed in Kin8 cells (Chapter II). Another possible explanation for functional 
differences between C a and Cy may be in the binding and release rates of the nucleotide 
substrates. The release of ADP is the rate-limiting step for C a  (34,35). It may be that 
overall structural differences between C a and Cy induce differences in the rate of the 
rate-limiting step. This hypothesis is explored in Chapter IV.
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CHAPTER IV
CHARACTERIZE THE KINETIC MECHANISM FOR PKA C a AND Cy 
THROUGH DETERMINATION OF THE RATE CONSTANTS FOR EACH 
CATALYTIC STEP OF THE PHOSPHOTRANSFERASE REACTION
ABSTRACT
Human PKA catalytic subunits C a and Cy share high homology in their primary 
structure (83% identity) but differ in biochemical function. The hypothesis explored here 
is that C a and Cy differ in their catalytic mechanisms, possibly in their substrate binding- 
rates, and that differences in their mechanisms translate to differences in their 
biochemical function. To this end recombinant C a nucleotide binding rates were 
determined and compared to the Cy ADP off-rate through stopped-flow analysis, using 
mant-ATP and mant-ADP. The Ca-ATP on and off rates were determined (1.6 x 106 M '1 
s’1 and 174 s '1 respectively) and found to be in good agreement with the literature. The 
C a  ADP dissociation rate (33 s '1) was slower than the ATP on-rate at physiological ATP 
concentrations, which suggests that ADP release is the rate-limiting step. However, a 
second slower rate was measured for mant-ATP binding (19 s '1), which may suggest that 
mant-ADP dissociation is not the rate-limiting step. Recombinant his6-Cy was used to 
measure its mant-ADP-off rate, a step where divergence in the catalytic mechanism from 
C a could explain differences in biochemical function. The signal measured for the Cy 
ADP off-rate was reproducible but very low (4 s '1). The measured ADP-off rate for C a  is
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about 9-times faster than that o f Cy, a result that is in agreement with differences in their 
steady-state kinetics. The physiological ramifications o f biochemical difference between 
C a  and Cy still needs to be determined through studies o f the isoforms in vivo and in the 
intact cell.
INTRODUCTION
Human PKA catalytic subunits C a and Cy share high homology in their primary 
structure (83% identity) but differ in their function. Differences include CREB-mediated 
transcription regulation and steady-state kinetics (5,105), where Ca-regulated 
transcriptional activation is 3-10 times higher than that of Cy and Cy-steady-state kinetics 
are 10-times slower than that of C a for most substrates tested (20). It is of interest to 
establish what factors contribute to these differences, which may manifest themselves 
physiologically. Several approaches have been attempted with little success to elucidate 
structural differences between C a and Cy that could be responsible for their functional 
differences (Chapters II and III). The hypothesis explored here is that C a and Cy differ in 
their catalytic mechanisms, either in their substrate binding-rates or product dissociation 
rates, and that differences in their mechanisms translate to differences in their 
biochemical function.
The C a catalytic mechanism has been well characterized through stopped-flow 
analysis, viscosometric analysis, characterization o f point mutants and steady-state 
kinetic characterization (34,87,155,156). The mechanism is described as a sequential or 
ordered Bi-Bi mechanism (Figure 16) where ATP binds PKA first, causing a 
conformational change that allows for the binding of the phosphoacceptor, followed by 
an associative, inline transfer of the y-phosphate from ATP onto the acceptor (reviewed
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in (157)). Once phosphorylated, the phospho-substrate is released, followed by the 
release of ADP, which has been proposed to be the rate-limiting step o f this mechanism 
(34). Here it was decided to compare recombinant C a  and Cy binding rates for ATP and 
ADP because the binding rates of the phospho-acceptor substrate vary depending on its 
nature and proper progression of the reaction depends on ATP binding the active site 
before the phospho-acceptor (Figure 16). The proper binding order o f the substrates is 
important to the progression of the catalytic mechanism as illustrated by the fact that 
when the phospho-acceptor binds C a before ATP the enzyme becomes locked-up in this 
species (Ca-S-ATP) and contributes little to the total phospho-substrate (p-substrate) 
generated (157) (Figure 16).
Analysis of the C a  and Cy catalytic mechanism was done here through stopped- 
flow analysis, using ATP and ADP conjugated to a N-methylanthraniloyl (mant) 
fluorophore through the ribose ring (Figure 16). This fluorphore is smaller than most 
flurophores decreasing the perturbation in the enzyme reaction. Furthermore the 
absorption and emission properties of mant are distinct from those of proteins and nucleic 
acids, has a long fluorescent halve-life, and has high sensitivity to small changes in its 
environment.
Using stopped-flow the Ca-ATP on and off rates were measured and found to be 
in good agreement with the literature (155). The homogenous purification of recombinant 
his6-Cy proved to be difficult, but enough was attained to measure the Cy ADP-off rate, a 
step where divergence in the catalytic mechanism of these two isoforms could explain 
differences in biochemical function
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SUBSTRATE 
ATP
P - SUBSTRATE
i
C - ATP - C - ADP I
SUBSTRATE P - SUBSTRATE 
ADP
SUBSTRATE
F ig 16. Diagram depicting the Cleland shorthand notation for the C a  
catalytic mechanism. The reported mechanism for C a (outlined with the bold 
line) is an ordered Bi Bi mechanism where ATP and then the phospho-acceptor 
(substrate) bind C a, followed by the transfer of the ATP y-phosphate to the 
substrate, the release of the phospho-substrate and finally release of ADP (the 
reported rate-limiting step). The phospho-acceptor can also bind before the ATP 
(outlined with the thin line), but this forms a catalytically slow intermediate that 
cannot contribute to the overall mechanism.
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. The measured ADP-off rate for C a was about 9-times faster than that o f Cy, a result that 
is in agreement with steady-state kinetics measurements, but one that needs to be 
repeated for validation. Unfortunately making this measurement required the use of the 
entire stock of purified Cy and purification of recombinant Cy still remains a challenge, 
so at present repeating this measurement cannot be done. The result from this experiment 
provides a tempting explanation to the biochemical differences observed between C a  and 
Cy, suggesting that C a releases its product (ADP) more rapidly than Cy during the rate- 
limiting step of the reaction. Thus, since Cy cannot catalyze a reaction any faster than the 
slowest step of its catalytic mechanism and this step is nine times slower than that of C a, 
it is possible to outline a mechanism based on their rate differences for the rate-limiting 
step to explain difference in their biochemical function, which is explored here.
MA TERIALS AND METHODS
Plaque Assay and Viral Stock Amplification -  To determine the titer of recombinant 
baculovirus stock, Sf9 cells from a spinner flask were added to 60 mm plates 
(1.5xl06/plate) and treated with 0.5 mL of viral stock dilutions (initially 10~'-10"3) for one 
hour, room temperature, with continuous rocking. After an hour the virus stock was 
removed and the cells were covered with a 5 mL overlay of 0.5% agarose in growth 
media (SeaPlaque Agarose, low gelling temperature, FMC) and incubated at 27°C for 
five days. The cells were then stained with viral dye overlay by covering each plate with 
3.3 mL 0.06 mg/mL Neutral Red (3.3mg/mL stock, Sigma) in 0.5% agarose and 
incubated at 27°C overnight (Figure 18). Plates were analyzed by counting number of 
plaques/plate on a white light transilluminator and calculating plaque forming units (pfu)
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as follows: pfu/mL = (averageplaques/plate) x  2 x  (viral stock dilution).
Viral stocks were amplified by adding 0.25 mL viral stock to 15 x 106 Sf9 cells in 
a T162 cm flask, rocking flask for one hour at RT, adding 15 mL growth media and 
incubating at 27°C for five days. Supernatant was harvested and characterized through 
plaque assay to determine final titer. Optimal titer range is 106-107 pfu/mL.
Expression o f  his-tagged Catalytic Subunits -  The 1.2 kb Cy cDNAs (158) was cloned 
separately into the BamRl site of baculovirus transfer vector pVL1393 (Invitrogen). 
Homologous recombination to produce Cy baculovirus stocks occurred through 
cotransfection o f 2x l06 Sf9 cells for 4 hours at 27°C with 2 pg baculovirus DNA 
(AcNPV DNA) and 3 pg o f pVL1393-Cy transfer plasmids. Recombinant Cy stocks were 
amplified in Sf9 cells (Gibco) and plaque purified according to the manufacturer’s 
protocols (Invitrogen). Clones were selected based on positive kinase activity and the 
highest expressing recombinant C-subunit baculovirus stocks were chosen for further 
studies. Isolates were further amplified, quantified through plaque assays (expressed as 
pfu/mL) and then used to infect Sf9 insect cells for protein expression and purification.
For expression of Cy in Sf9 insect cells (Gibco) cells were cultured at 27°C in 
ExCell 420 media (JRH) serum free medium. Sf9 cells were grown in monolayer to 70% 
confluency (approximately 15xl06 cells/T150 flask), infected with baculovirus (80 
pfu/cell) and incubated for three days at 27°C. Sf9 cells that overexpress kinases, such as 
C a or Cy, undergo morphological changes that are distinct from the classic rounding 
morphology induced by wt baculovirus infection (159). The morphology of infected Sf9 
cells changed from small spherical cells (Figure 19A) to large round cells (1-2 days post­
infection) and finally developed single or some times double extend processes, which
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Fig 18. Picture of plaques following neutral red overlay. The four plates in the 
picture include control (C), along with 10'5 (-5), 10'6 (-6), and 10'7 (-7) dilutions of 
the his6-Cy expressing baculovirus stock.
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F ig. 19. Micrograph of morphology changes observed in Sf9 Cells after a three- 
day infection with Cy-gene carrying baculovirus. A, A micrograph o f uninfected 
Sf9 cells which exhibit classic Sf9 cell morphology. B, A micrograph of Sf9 cells 
infected three days, expressing Cy, which indirectly causes the polymerization of 
cytoskeletal proteins. This leads to the formation o f structural processes protruding 
from the cells (marked by the arrows), which resemble tails and serve as markers for 
Cy expression in the cell. Images were taken on an Olympus 1X70 inverted 
microscope with an Olympus CCD computer-controlled camera (Olympus America, 
Melville, NY).
B
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resembled tails (2 to 3 days post-infection) (Figure 19B). Similar morphological changes 
were observed in Sf9 cells expressing recombinant C a, however C a was not purified 
from Sf9 cells as its expression in this cell line was lytic and resulted in large loss of the 
protein prior to purification step (2 0 ).
For purification of human his6-Cy, Sf9 cells were grown to 70% confluence in 
spinner flasks (approximately 2 xlO6 cells/mL in 1L of growth media), infected with his6- 
Cy-baculovirus (80 pfu/cell) and incubated for three days at 27°C. Infected Sf9 cells were 
centrifuged (1,500 x g for 5 min) and stored at -80°C as 500 xlO6 cell/aliquots. Aliquots 
were homogenized in 15 mL binding buffer (50 mM KPO4, pH [7.9], 250 mM KC1) with 
2 mM PMSF using a ground glass dounce homogenizer (Pyrex). The homogenate was 
centrifuged (15,800 x g for 30 min at 4°C) and the supernatant was applied to a 15 mL 
Ni-IMAC column (=3x107 cells/ml resin). The column was washed with 3 CV of binding 
buffer, 10 CV of wash buffer (binding buffer with 60 mM imidazole) and eluted with an 
80 mL 60-600 mM imidazole gradient in elution buffer (binding buffer adjusted to pH 
[6.4]), while collecting 1 mL fractions. Fractions were assayed for kinase activity. 
Fractions exhibiting the highest specific activity were pooled and concentrated with 
Amicon Ultra-15 Centrifugal Filter Devices (Millipore, 10, 000 MWCO). The protein 
peak elution occurred at ~ 350 mM imidazole. The purified protein had a SA of 0.5 U/mg 
and was analyzed for purity by SDS-PAGE subjected to silver staining, coomassie 
staining or Sypro Ruby Staining (Molecular Probes).
Recombinant murine hisio-Ca was expressed from a pET16b expression vector 
from IPTG (0.40 mM final) induced BL21(DE3)pLysS (Novagen) transformed 
competent cells grown overnight in the presence of ampicillin (50pg/mL) at 37°C. For
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1L of transformed cells (~3g cells), cell suspension was centrifuged at 11, 500 g (JA14 
rotor, Beckman J2-MI), at 4°C, for 2h. The supernatant was discarded and the cell pellet 
stored at -80°C. Cells were harvested in 20 mL binding buffer (50 mM NaPCL, pH [7.9], 
0.5 M NaCl, 10% glycerol) with 2 mM PMSF. The cells suspension was sonicated 5 x 
6sec (mid-setting on a 550 Sonic Dismembrator, Fisher Scientific), while on ice, with 1 
min between sonications. Extract was loaded onto a pre-equilibrated 7 mL Ni-IMAC 
column (ProBond, Invitrogen) and washed with 10 CV wash buffer (binding buffer with 
60 mM imidazole). Initially the enzyme was eluted with an 80 mL 0.06-1.0 mM 
imidazole gradient in binding buffer, while collecting 1 mL fractions, with the elution 
peak at about 350 mM imidazole, followed by separation on a Sephadex S300 gel 
filtration column. It was subsequently found that similar results were obtained if the 
protein was eluted with a 20 mL imidazole gradient off a 2 mL Ni-IMAC column, while 
forgoing the gel filtration step. Both approaches provided about 5.5 U/mg of pure hisio- 
Ca. Unphosphorylated hisio-Ca was expressed in BL21(DE3)pLysS cells in the presence 
of 100 pM H89 (10 mM stock in DMSO) and purified through Ni-IMAC 
chromatography.
Protein assay- total protein was analyzed via three different methods, Protein Assay 
(BioRad), based on the Bradford reaction assay, NanoOrange (Molecular Probes), a 
fluorescent protein assay, or through use of the extinction coefficient for each of the 
proteins. All three methods provided comparable values (provide extinction coefficients 
for each catalytic subunits).
Stopped-flow kinetic measurements- All transient kinetic measurements were made 
similar to methods described elsewhere (155,160) using a KinTec stopped-flow
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spectrometer. Briefly, samples were mixed 1:1 in the instrument cuvet using two (single­
mixing) or three (double-mixing) syringes. The excitation wavelength was 290 nm, and 
fluorescence emission was measured using a 420 nm cutoff filter. The instrument 
collected data points for 0 to 12000 ms time frames in each experiment (logarithmic time 
base). For data analysis, the average of three individual traces was used and the 
fluorescence data were recorded as volts. Rate constants and amplitudes were obtained by 
fitting of the data to equations describing a single or double exponential growth/decay 
using KinTec software. All fluorescence measurements were made in buffers containing 
50 mM Mops, pH 7.0, measured at both 4°C and 25°C.
Protein Kinase Assays And Steady State Kinetic Determinations -  In the standard kinase
32assay, the activity of the C-subunits was determined by the transfer o f y- 'P-ATP (200 
pM) to peptide (65 pM Kemptide, LRRASLG) in the presence and absence o f the protein 
kinase inhibitor peptide (amino acids 5-24) PKI5.24 (2 pM), as previously described (20).
Steady-state kinetic constants (Km and Vmax) for purified C a and Cy were 
determined using a modified protein kinase assay. Briefly, a 50 pL reaction mixture 
contained 30 pL test mix (50 mM Tris-HCl (pH 7.0), 200 pM ATP, 20 mM magnesium 
acetate, 10 mM DTT, and y32P-ATP (300 cpm/pmol)) and 10 pL substrate. The reactions 
was initiated with the addition of 10 pL of the enzyme and incubated at 30 C for ten 
minutes, spotted on P-81 paper and placed in 75 mM phosphoric acid to terminate the 
reaction. The strips were washed in phosphoric acid 4 or 5 times, for ten minutes each 
wash, washed once in ethanol, and allowed to dry before being placing in liquid 
scintillant. Specific activity measurements were incubated for 2, 4, 6, 8 and 10 minutes. 
Various concentrations of the substrates kemptide (1.9-435 pM) were used to determine
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Km and Vmax values. The determination of apparent Km for the phosphate donor substrate 
ATP was done using a non-radioactive kinase assay (Appendix H).
Immunoblots -  Samples were separated on a 9% SDS-PAGE gels with a 4% stacking gel, 
transferred and treated with antibodies as described previously (105). A rabbit polyclonal 
antibody to C a from Santa Cruz Biotechnology (sc-903, 1:1000) that cross-reacts with 
both C a and Cy was used to identify the purified recombinant proteins. Following 
primary antibody treatment and washes, the membranes were incubated with HRP- 
conjugated anti-rabbit polyclonal antibody (Amersham Biosciences) at a 1:1000 dilution 
and washed. The membranes were developed using Amersham’s ECL detection kit and 
imaged electronically (BioRad’s VersaDoc imaging system).
RESULTS
Purification and characterization o f  his-Ca and Cy-  Pure recombinant Cy had previously 
been obtained using a non-conjugated protein, requiring two chromatographic steps for 
purification, first with carboxymethyl (CM) ion-exchange chromatography followed by gel 
filtration chromatography (20). The advent of LC-MS/MS technology (please see Chapter 
III) provided one more method to characterize purified recombinant Cy. LC-MS/MS 
analysis of in-solution digest of purified Cy (method described in Chapter III) identified 
peptides to six proteins (Figure 20): (1) baculovirus p48 (YFNQSLIVDSK, Xcorr 3.97, 
ACorr= 0.16; YSDENINLLIHK Xcorr 3.78, ACorr= 0.25; SSFENQANNTDNIHNVK, 
Xcorr 3.32, ACorr= 0.41), (2) serum albumin precursor (LGEYGFQNALIVR, Xcorr 4.13, 
ACorr= 0.31; DAFLGCFLYEYSR, Xcorr 3.28, ACorr= 0.42; HLVDEPQNLIK, Xcorr
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F ig .  2 0 .  Liquid chromatography coupled to mass spectrometry analysis of 
sample containing purified recombinant Cy. A, chromatography coupled to B, 
mass spectrometry (mass/charge or m/z) analysis of trypsin digested Cy containing 
sample revealed peptide fragments that matched sequences of various proteins, 
including bovine serum albumin, human keratin, and baculovirous protein p48. 
None of the fragments were matched the Cy sequence.
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2.99, ACorr= 0.25; KVPQVSTPTLVEVSR, Xcorr 2.83, ACorr= 0.14), (3) human keratin 
type II cytoskeletal 1 (SLDLDSIIAEVK, Xcorr 2.79, ACorr= 0.17; TLLEGEESR, Xcorr 
2.54, ACorr= 0.12), (4) GDP dissociation inhibitor
(LS AIY GGTYMLDKPIDEIVLGEGGK, Xcorr 5.77, ACon= 0.48;
SPYLYPMYGLGELPQGFAR. Xcorr 5.43, ACorr= 0.42), (5) chain A crystal structure of 
caspase-8/p35 complex (DYSDQMDGFHDSIK, Xcorr 5.77, ACorr= 0.48); and (6) E 
chain, leech-derived tryptase inhibitor (IITHPNFNGNTLDNDIMLIK, Xcorr 4.30, ACorr= 
0.40). None of the peptides identified corresponded to Cy, suggesting that Cy was not the 
most abundant protein isolated from its purification. This became a major concern because 
all of the enzyme assays performed to characterize Cy are dependent on an accurate 
measure of its concentration in the reaction, which becomes a problem when a contaminant 
is present in the sample.
Another approach was devised to purify baculovirus-expressed recombinant Cy 
from Sf9 cells to improve resolution during purification and to minimize the 
chromatographic step required for purification. The Cy ORF was inserted into a vector that 
would express it with the addition of six histidines to its amino terminus to allow for 
immobilized metal affinity chromatography (IMAC) purification using Ni2+- or Co2+- 
chelated resin (Described in Materials and Methods). After comparing Ni and Co resin for 
Cy purification, it was found that Cy had a higher affinity for the Ni-chelated resin (eluting 
at350 mM imidazole) than for Co-chelated resin (eluting at 150 mM imidazole), making 
Ni-resin favorable to minimize the loss of Cy during binding and washing steps of the 
purification. But this approach still proved difficult in part because it was difficult to 
optimize Cy expression in Sf9 cells. Also, Sf9 cells contain a population of proteins that
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bind the Ni resin (Figure 21). Because of this, resolution of endogenous Sf9 proteins from 
baculovirus expressed Cy was also difficult (Figure 21). Fractions containing Cy had to be 
selected after protein levels in the elution profile dropped, leading to a loss of Cy in the 
shoulder where overlapping occurred between Cy and Sf9 cell-protein (Figure 21). Once 
expression and purification conditions were optimized Cy was expressed and purified from 
Sf9 cells with yields of 2mg of recombinant protein that were >80% pure (Figure 22). 
Fligh-yield, homogeneous purification of C a ectopically expressed in bacteria is relatively 
straightforward and well documented (96,139,161). Hisio-Ca was purified here so that both 
isoforms could be compared containing the same type of modification.
Recombinant his6-Cy and hisio-Ca were characterized through steady-state kinetics 
following purification using Kemptide as a substrate, and were analyzed with Eaddie- 
Hofstee plots (Figure 23). Results from this characterization suggest that Cy’s affinity for 
Kemptide is about 5 times higher than previously reported with the non-his tagged isozyme 
(Km= 4 + 2 pM, average ± standard error, n= 9), while hisio-Ca exhibited similar affinity 
for Kemptide as measured with the non-his tagged isozyme (Km= 23 + 10 pM, average ± 
standard error, n= 7). These averages represent measurements made from several different 
preparations over the past five years. An average for their Vmax could not be made, as many 
of the preparations made were not pure enough for an accurate determination of Cy protein 
concentration in the preparation.
Stopped-flow characterization o f Ca-ATP binding rates- The ATP binding rates were 
determined with C a, but not Cy, because of the high amounts of C a readily obtained
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F ig . 21. Cy nickel IMAC purification profile. This profile represents the best 
resolution obtained between cellular lysate proteins (closed circles) and Cy 
activity (open circles). In this experiment fractions 45-57 were pooled together 
for the concentration step to avoid inclusion of contaminant proteins.
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F ig . 22. SDS-PAGE analysis of C-subunit purification. Purification o f 
both C-subunits was followed by silver stain gel analysis. A, purification 
profile for his6-Cy, which corresponds to the purification profile in Figure 20. 
Lane 1, molecular weight marker; 2, empty; 3, extract; 4, flow through; 5, 
wash 1; 6, wash 2; 7, elution of fractions 37-44; 8, elution of fractions 45-57; 
9, empty; 10 pooled and concentrated fractions 45-57. B, gel showing 
purified hisio-Ca.
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F ig . 23. Eadie-Hofstee plots for steady-state kinetics with 
Kemptide. Steady-state kinetics were determined through standard 
kinase assays. The slope of each plot was used to determine and 
compare Km values, which were, A, 8.5 pM for C a  and B,.3.8 pM for 
Cy.
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through expression and purification from bacteria and the low expression levels of Cy in 
Sf9 cells. Stopped-flow characterization of C a has been done using several approaches 
(38,155). The approach used here employs fluorescence resonance energy transfer (FRET) 
to measure the binding and release of ATP from C a ’s active site (155). The principal of 
this approach is that exciting tryptophans in the C a active site at 290 nm, releases energy 
(320-340 nm) exciting mantATP as it comes into proximity with the C a  active site, re- 
emitting energy at >420 nm as it does so, which is measured by the stopped-flow 
fluorometer. Thus, as mantATP binds the C a active site an increase in fluorescence is 
measured, recorded as volts, and plotted. The binding rate (or rates) is determined by the 
equation used to fit the hyperbolic curve measured.
Two rates were measured for Ca-mant-ATP binding at 25°C. The first rate (ki) is a 
very rapid increase in fluorescent signal followed by the second rate (k2), which is a slower 
decrease in signal (Figure 24). Rates ki and k2 were measured at several concentrations of 
mantATP and plotted (Figure 25). The slope for the first rate, ki, was found to be mantATP 
concentration-dependent (1.6 x 106 M/sec). The slope for k2 did not change with changing 
concentrations of mant-ATP (19 s"1). The slope of the k l linear-curve corresponds to C a ’s 
binding rate for mant-ATP, which is within experimental error of the value reported in the 
literature. As reported, this rate is very rapid, but not as rapid as diffusion-limited reaction 
rate (108), where the reaction occurs as rapidly as the molecules can encounter.
The mant-ATP binding was also measured at 4°C. At this temperature several 
interesting things were observed. First was that the mant-ATP binding rate is similar at 
both temperatures (ki(4°Q= 1.9 x 106 NT’sec"1). The second observation is that three rates 
were measured at 4°C (k2(4°c)= 0.3sec_1, k3(4»C)= O.Of^sec'1). The second and third rates at
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4°C are mant-ATP concentration independent. The second rate measures an increase in 
fluorescent signal (amplitude2oo pm mant-ATP= -0.0662) and the third rate measures a decrease 
in fluorescent signal (amplitude2oo pMmant-ATP= 0.0165).
The mant-ATP binding was also measured at 25°C in the presence o f Kemptide to 
determine whether the presence of the phospho-acceptor substrate affected the observed 
binding rate of the nucleotide substrate (Appendix J). This was done by mixing 13 pM C a 
from one syringe with 100 pM mant-ATP and varying concentrations of Kemptide (25-400 
pM) in the other syringe. The slopes for the two rates measured at 25°C, ki and k2, 
decreased very slightly with increasing amounts of Kemptide (kj Kemptide: y = -0.1961x + 
296.43, R2 = 0.3865; k2 Kemptide: y = -0.0063x + 11.038, R2 = 0.0278), but it is not clear if 
these slopes fall within the error measured for each rate. A similar trend is observed in the 
amplitudes for each rate (amplitude]KemPtide: y = -O.OOOlx - 0.1012, R2 = 0.5346; 
amplitude2Kemptide: y = -7 x 10'6x + 0.0123, R2 = 0.085). The correlation values for these 
curve fits are not very good, suggesting that there is little difference between the measured 
rates or amplitudes at each Kemptide concentration. However, there is a decrease in the 
amplitude of k2 relative to the amplitude measured in the absence of Kemptide, suggesting 
that Kemptide affects the step corresponding to k2 . The ATP-off rate for C a was 
determined through two independent approaches. The first was simply the y-intercept of 
Figure 25, the slowest rate of the mantATP binding rate curve, 174sec"'. The second 
approach was through double-mixing stopped-flow (Figure 26) In this approach mant-ATP 
was first mixed with C a, followed by a second mix with a high concentration of ATP (3 
mM). The ATP binds the C a active site, displacing mant-ATP as mant-ATP dissociates 
from the active site.
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F ig 24. Binding of mant-ATP to C a measured using stopped-flow 
spectroscopy. Time-dependent change (x-axis) in fluorescence in volts (y-axis) 
upon mixing 4 pM C a and 400 pM mant-ATP at 25°C. Two fluorescent signals 
are observed, ki, which increases with time and k2, which decreases with time.
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F ig . 25. Effects of total mant-ATP concentration (12.5-200 pM) at 
25°C. The plot shows rates k l and k2 measured against several 
concentrations o f mant-ATP (x-axis). A rate was measured for 400 pM 
mant-ATP, but this rate fell off the linear curve and did not fit a 
hyperbolic curve with statistical confidence.
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This rate is independent of ATP concentration and is measured as a decrease in 
fluorescence, which corresponds to the mant-ATP off-rate (174sec_1). As can be seen the 
value from this measure is in excellent agreement with the value obtained from the y- 
intercept in Figure 25 (173.65sec_1) and this value is in good agreement with the value 
reported in the literature (lOOsec-1)! 155).
Stopped-flow characterization o f  C a and Cy ADP dissociation rates-  Once satisfactory 
measures were made with mant-ATP and Ca, it was of interest to measure the mant-ADP 
off-rates for C a and Cy. The release of ADP is reported to be the slowest step in C a ’s 
mechanism (Figure 15), thus it is described as its rate-limiting step. This measure was done 
here through double-mixing experiments where the isoforms were pre-mixed with mant- 
ADP, followed by the addition of high concentrations of ATP (3mM). The Ca/mant-ADP- 
off rate (35sec'*) was determined from a fit of the curve measured as the fluorescent signal 
decreases while the mant-ADP is trapped off the catalytic subunit (Figure 26A), and is in 
agreement with the literature (75sec_l) (38,155). A very low signal was obtained when the 
same experiment was done with Cy (Figure 26B), but a reproducible rate was measured 
(4.1 ± 0.3 sec'1; Avg. + Std. Error, n = 3). The rate measured for the Cy mant-ADP off-rate 
is nine times slower than the C a rate. Unfortunately, this approach used the entire stock of 
purified Cy, and complications of Cy expression prevented repeating the experiment. 
DISCUSSION
Biochemically, C a and Cy differ in their steady-state kinetics for classic PKA substrates, 
including histone and Kemptide (20), specifically the Cy Vmax is ten-times lower than that 
of Ca. One possible explanation for this difference is that Cy has slower substrate binding
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F ig . 26. Double-mixing experiment trapping mant-ATP 
from C a at 20°C. 8 pM C a was pre-mixed with 200 pM mant­
ATP in one syringe, and then rapidly mixed with 3 mM Mg- 
ATP. The data was fit with a double-exponent function to 
obtain the rates k l=  174 s '1 and k2= 3.8 s '1.
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F ig . 27. Double-mixing experiment trapping mant-ADP from C a and 
Cy using ATP at 20°C. A, 12 pM C a was pre-mixed with 200 pM mant- 
ADP in one syringe and then rapidly mixed with 3 mM Mg-ATP. The data 
was fit with a double-exponent function to obtain the rate for k l=  34.5 s '1 
(amplitude= 0.277). B, 6 pM Cy was pre-mixed with 100 pM mant-ADP in 
one syringe and then rapidly mixed with 3 mM Mg-ATP. The data was fit 
with a double-exponent function. The first component was ignored here as it 
reflects an increase in mant-ADP. The rate for k2= 4.0 s-1 (amplitude= 
0.00749) is the rate for the dissociation of mant-ADP from Cy.
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and/or release rates, slowing down the rate of its catalytic mechanism. If  true, this would 
explain why Cy exhibits lower CREB-mediated reporter activity, as this mechanism 
depends on the C-subunit phosphorylating CREB at S I33 (162). Thus Cy would 
phosphorylate 0.1 of the CREB molecules that C a would, causing a ten-fold difference in 
reporter-activity measured, which is what is observed in some cell types (105). Here we 
studied the catalytic mechanisms of both C a and Cy through stopped-flow analysis using 
fluorescent-labeled ATP and ADP substrates, which are the first substrates to bind and last 
product to leave the C-subunit catalytic active site (34,155).
Two general classifications serve to describe the kinase kinetic mechanism based 
on the data from steady and pre-steady-state kinetic studies and crystal structure analysis of 
more than thirty kinases (163). Mono-substrate kinetics is a relatively simple model used to 
teach enzyme kinetics and is easily described by the Michaelis-Menten equation (164). 
However kinases catalyze the reaction between two substrates (a nucleotide triphosphate 
and a phosphoacceptor), making the reaction more complex. However, when the 
concentration for one substrate is held constant the Michaelis-Menten equation still holds 
true for the second substrate (165), providing an approach to study the two-substrate 
mechanism of an enzyme. The steady-state kinetic characterization is determined once all 
of the reaction components (enzyme, co-enzymes and substrates) have reached equilibrium. 
This provides a lot of information but is limited because this type of characterization is not 
able to easily differentiate the binding and dissociation rates for individual ligands. 
Discerning binding rates for each ligand in an enzymatic reaction helps to develop a model 
for the enzyme’s reaction mechanism. A technique often used to measure the catalytic rates 
is stopped-flow, which measures the rates for each ligand, when possible, before
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equilibrium between enzyme and substrates is established (166). Thus, this technique 
measures an enzyme’s pre-steady state kinetics.
One mechanism used by kinases is the Bi-Bi mechanism (Figure 15) where the 
order in which the NTP and the phospho-acceptor substrates bind the enzyme may 
(ordered Bi Bi) or may not (random Bi Bi) matter. The key to this mechanism is that no 
phospho-enzyme intermediate is formed instead the enzyme directly transfers the NTP 
phosphoryl group to the phospho-acceptor substrate. Hexokinase is an example o f an 
enzyme that follows this mechanism; serine-threonine kinases also follow this 
mechanism (157,163,167). The second mechanism for kinases is the Ping Pong Bi Bi 
mechanism wherein the kinase binds an NTP and catalyzes the transfer of the NTP 
phosphoryl group to its own active site. The remaining NDP is then released from the 
kinase, leaving behind a phospho-kinase enzyme intermediate, which then binds the final 
phospho-acceptor substrate, catalyzing the transfer o f the phosphoryl group to the 
substrate. Examples of this mechanism include alkaline phosphatase, tyrosine 
phosphotransferases, nucleotide diphosphate kinase, and P-ATPase (168). A point of 
controversy concerning protein kinase that utilize the ordered Bi Bi mechanism is 
whether the phosphoryl transfer occurs through an associative ( S n 2 )  mechanism, where 
there is no phosphoryl intermediate formed between the enzyme and substrates within the 
active site of the enzyme or a dissociative ( S n I )  mechanism where a phosphoryl 
intermediate forms prior to phosphoryl transfer (26,169,170).
The mechanism described for C a is an ordered Bi Bi mechanism (Figure 15)
(34,171,172), where the literature favors the in-line associative transfer of the phosphate, 
and the release o f ADP as the rate-limiting step (34,35,155). The results presented here,
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while far from being conclusive, seem to support the published mechanism for C a, where 
the ATP binding rate is very rapid (Figure 24) and the ADP release is much slower 
(Figures 26). However, the results presented here and published elsewhere (155) make it 
clear that the C a  catalytic mechanism is not as straightforward as depicted in Figure 15
(171,172). Stopped-flow analysis o f the ligand binding rates for ATP and ADP were 
studied here through use of fluorophore conjugates nucleotides, mantATP and mant- 
ADP, which serve as good analogues to study ATP and ADP binding to C a (155). 
Stopped-flow analysis presented here of mant-ATP binding C a at 25°C measures two 
rates, ki which is a rapid increase, mant-ATP concentration-dependent rate, and k2 which 
is a slow decrease, mant-ATP concentration-independent rate. This suggests that there are 
at least two steps involved in the binding o f mant-ATP. Ni et al. measure three rates for 
this step (155), the first two match the ones measured here, and the third one is also 
ligand concentration-independent but slower than k2, suggesting that there may be a third 
step to C a binding mant-ATP. Results presented here of mant-ATP binding C a at 4°C 
measure three rates, but unlike the published work at 25°C the second rate also measures 
a slow increase in fluorescent signal, thus at 4°C there are two rates that measure an 
increase in signal and a third that measures a decrease in signal. The third rate measured 
at 4°C would coincide with k2 measured at 25°C, but it is much slower than would be 
predicted by estimating a two-fold decrease every 10°C, suggesting that this rate is very 
temperature dependent, which may mean it is measuring a conformational change in Ca. 
Between the work presented here at 4°C and 25°C and the published work there are four 
measured rates, suggesting that there may be three steps in the binding of mant-ATP. The 
mant-ATP off-rate for C a was arrived at via to independent approaches, which were in
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very good agreement with each other (174 sec'1) and in good agreement with the 
published work (165 sec'1 and 190 sec'1) (155).
The C a mant-ATP on-rate was also measured in the presence o f Kemptide, which 
is a second substrate for C a, to determine if having both substrates present affected either 
of the mant-ATP rates measured at 25°C. A common trend was observed in this 
experiment for both rates measured and their corresponding amplitudes, and that was that 
there seemed to be a decrease in both rates and amplitude as the Kemptide concentrations 
increased. This would suggest that high concentrations of the phosphoacceptor would 
slow down the ATP binding-rate. One interpretation of this may be that at higher 
phosphoacceptor concentrations two enzyme species are formed, one wherein the ATP 
bound before the phosphoacceptor and a second where the phosphoacceptor bound the 
kinase before ATP. It is not clear without further experiments whether the later species 
described would undergo FRET, but if  the phosphoacceptor were to bind the kinase first 
this may lead to a change in the amplitude o f second signal. However the correlation 
values for these experiments are very low suggesting that either there were outliers in the 
experiment or that there really is no trend and having Kemptide present does not affect 
the ATP binding rate. At this point the experiment has not been repeated enough times to 
statistically discern between these two possibilities.
The ADP off-rate for both C a and Cy was measured through double mixing 
experiments, in which the kinase was first mixed with mantADP and then mixed with 
ATP. The results presented here agree with the release of ADP as the being slower than 
ATP on or off-rates, and thus would fit as the rate-limiting step for C a. The C a mant- 
ADP off-rate was approximately five-times slower than the ATP off-rate and ten-times
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slower than the measured ATP-on rate. These rates are also in good agreement with the 
reported mechanism for C a, where ATP binds first, followed by binding of the 
phosphoacceptor, the phophorylation of this substrate and the release of the 
phosphorylated substrate, leaving ADP in the active site, which is released last (Figure 
15). Furthermore, the results presented here for C a are in good agreement with the values 
reported in the literature (155). Flowever, this mechanism (outlined in Equation 2) does 
not take into account the second rate (k2) measured for mant-ATP binding C a, which was 
measured here as being slower than the mant-ADP off-rate (k7), but was reported 
elsewhere not to be statistically different from the mant-ADP off-rate (155). This raises 
the question, is mant-ADP dissociation truly the rate-limiting step for this reaction? The 
discrepancy rests with which experimental values are accepted to be true.
One approached used here to try and answer this question was to determine the 
turn-over rate or kcat for the purified C a used in these experiments and compare it to the 
different rates measured here. While the significance of kcat to a mechanism depends on 
the nature o f the mechanism it should coincide with the rate-limiting step of the reaction. 
Upon calculating the turn-over rate for the pure C a used in these experiments it was 
found to be about ten-times slower (3.9 sec'1) than the slowest rate measured or any 
published turn-over rates which range from 52 sec'1 to 20 sec'1 (37,87,156). This suggests 
that there was about five-to-ten-times less active C a in the prep used here as the 
calculation depends on the total concentration o f enzyme used (kcat= Vmax/[Etot]). This 
observation may explain why a third rate (k3) was not measured at 25°C, as here we may 
have had less available enzyme in the reaction as in the published work (155). A decrease
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in the amount of enzyme would cause a decrease in the amplitude of the signal measured, 
making it more difficult to fit the curve to the low signal o f a slow rate.
Based on the work presented here and published elsewhere there are at least seven 
different steps to the C a catalytic mechanism. A mechanism is displayed in Equation 2 
that attempts to consolidate all of the rates measured or published for C a, where ki (1.6 x 
106 M '1 s '1), k_i (174 s '1), K2 (19 s '1) and k7 (35 s '1) were determined here. Rate k3 is 
based on published work (155). Rate k4 , while not measured will depend on the catalytic
k, k2 k3 k4 ^5 (2)
C + ATP <-> C*ATP <-> C*ATP’ C*ATP + S o  C*ATP*S <->
k.j k-2 k_3 k-4 k-5
k6 k7
C*ADP*P C*ADP + P <-> C + ADP
k_6 k_7
subunit (C) affinity for the phosphor-acceptor (S), k5 is the rate of the chemical phosphor- 
transfer and k6 will depend on the dissociation rate of the phosphorylation product (P). It 
is not clear from the experiments done here if the C a Km for Kemptide (23 pM) is 
equivalent to kfi in Equation 2.
This is the first time pre-steady state kinetics have been measured with Cy. The 
challenge for this experiment was in isolating sufficient protein to make the 
measurements. Here sufficient Cy was isolated to measure its binding rate with one 
nucleotide. As the release of ADP is the rate-limiting step for C a, it was felt that this was 
a likely step where C a and Cy mechanisms might diverge and thus chose to use what 
sample was available from purifying Cy to study its ADP off-rate. The signal measured 
for this step was very weak and did not provide a curve that was very distinct from the
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mantADP background signal. However, the signal obtained from double mixing 
mantADP and ATP to measure the off-rate provided a reproducible exponential curve fit 
for Cy with a slope nine-times slower than that of Ca. Because the signal was so low it is 
not clear if  the slope measured is accurate or if the weak signal is due to insufficient 
quantities of functional protein. The latter is a likely possibility because pure recombinant 
Cy is not very stable at -80°C or in N2 (/), so it is possible that only a portion o f the 
protein in the purification preparation was functional, which would yield a lower signal in 
the stopped-flow experiments. However, the concentrations o f enzyme used for C a  and 
Cy were calculated to be the same in these experiments and the steady-state kinetic 
measures with this Cy prep allowed for the highest dilution o f Cy made to date, lOOx, 
suggesting that there was more enzyme than usual obtained from this purification, but 
this does not mean that there was enough active Cy for this type of experiment. Once 
sufficient Cy can be purified to repeat these experiments the enzyme should be tested in 
binding assays with pure recombinant R-subunits, an approach that will stochiometrically 
identify the concentration of active Cy in the preparation, as only functional Cy will bind 
the R-subunit (173). This measure will provide a starting point for an accurate measure of 
each isoforms tested in the stopped-flow experiments.
If the values measured here for C a and Cy are accepted as accurate, then the 
difference in rates for the release of ADP can be used to outline an equation that could 
explain why Cy is kinetically slower than C a (Equation 3), wherein if the equilibrium 
rate between the different species of C-ADP (K) or the dissociation rate o f C and ADP (k- 
ADP) is very different between the two catalytic subunits the equation could explain 
differences observed (Appendix E).
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Differences in reaction rates may be due to overall differences in their tertiary 
structure, as illustrated by Cy having a smaller stoke’s radii (20) (Appendix F), suggesting 
an overall different shape than C a. This may affect interactions in the active site making 
Cy less efficient at phosphorylating, as demonstrated by Vmax:Km ratios for Kemptide and
K  k-ADP n )
C*-ADP <==> C-ADP —> C + ADP
Histone (20). The difference in Stoke’s radius between the two catalytic subunits may also 
reflect that purified recombinant his-Cy is improperly folded. But this is unlikely because 
the measurement of the radius is dependent on determining where the protein elutes off 
size-exclusion chromatography and this is determined by kinase activity. This is, the 
measured radius is based on an active enzyme, which should be folded sufficiently to be 
active. It is also possible that his-Cy is miss-folded, still active, but not as active as 
endogenous Cy. But this is difficult to confirm as endogenously expressed Cy has yet to be 
isolated from any tissue and characterized.
There are several key residues that are important to the inline-transfer between ATP 
and the phosphoacceptor, including K72, the G-triad, G50, G52 and G55, D166, K168, 
N171 and D184 (118,157,174). All of these are conserved between C a and Cy and depend 
on the distances within the active site for proper proximity to the substrates. It is possible 
that these distances are disrupted in Cy, affecting the interaction between the residues and 
the substrates, and this effect is manifested as a slower catalytic rate for Cy. This model 
would be difficult to test through point-mutants as it depends on determining the position of 
each residue within Cy’s active site. The best way to test this is through determining the
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crystal structure of Cy, an approach that requires high quantities of highly pure protein, 
something that remains elusive in the characterization of Cy.
The results presented here however support the hypothesis that differences in 
kinetics between C a and Cy are in part due to differences in the rates o f their rate-liming 
step as the differences observed in this rate-limiting step agree with differences observed in 
steady-state kinetics and transient reporter assays. The physiological ramifications of the 
biochemical difference between C a and Cy still needs to be determined through studies of 
the isoforms in vivo and in the intact cell.
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CHAPTER V
DIFFERENTIAL EXPRESSION OF cAMP-DEPENDENT PRO TEIN  KINASE 
C a  AND Cy ISOFORM S IN U-937 CELLS
ABSTRACT
The cAMP-dependent protein kinase (PKA) catalytic subunits Cy and C a share 
83% identity in primary structure but differ in chromosomal location, gene structure, 
gene transcription regulation, kinetics, and specificity for peptide substrates and 
pseudosubstrates. In contrast to the ubiquitous expression of C a, Cy is primate-specific 
and mRNA has been identified only in human testes. For the first time we present the 
selective identification of endogenous Cy protein and mRNA expressed in human U-937 
cells. Increases in protein kinase inhibitor (PKI)-insensitive, cAMP-dependent kinase 
activity following 8-CPT-cAMP-induced differentiation of U-937 cells suggested an 
increase in Cy expression during differentiation, while total PKA catalytic activity did not 
change. A new antibody identified a 40-kDa band following differentiation of U-937 
cells and RT-PCR/RFLP analysis demonstrated that Cy mRNA was present before and 
after differentiation. DEAE chromatographic analysis of U-937 cells showed that the 
PKA profile changed from similar levels of type I and type II PKA in undifferentiated 
cells to 100% type I in differentiated U-937 cells. Furthermore, 60% of PKI-insensitive, 
cAMP-dependent activity in U-937 cells was associated with type I PKA suggesting Cy 
favors association with type I PKA in this cell line. These results expand our
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
105
understanding of structure-function roles for PKA isoforms in cell differentiation and 
function. Furthermore the increase in Cy expression during U-937 differentiation suggests 
a novel function for Cy in the cell.
INTRODUCTION
The cyclic AMP-dependent protein kinase (PKA, EC 2.7.1.37) is a member of the 
AGC serine/threonine kinase family (2), which phosphorylates hundreds of substrates 
involved in numerous physiological processes, such as energy metabolism, cell division, 
proliferation, apoptosis, and differentiation (1). PKA is present at varying concentrations 
in all tissue types (42,43) and exists as an inactive holoenzyme consisting o f a regulatory 
subunit (R) dimer and two catalytic subunit (C) monomers in the absence o f cAMP. Two 
types of PKA exist in the cell, type I and type II, determined by the R subunit isoform 
present in the holoenzyme. There are four known Homo sapiens genes for the R subunit: 
R Ia, Rip, R lla, and RIIp. Classically, PKA type I elutes from a DEAE column at lower 
NaCl concentrations than type II (175). There are three genes for the C-subunit expressed 
in Homo sapiens: C a, CP, and Cy (45). Human C a and CP share the highest degree of 
homology in their primary amino acid sequence (93% identity) and have multiple splice 
variants (49-52). C a and Cy are highly homologous exhibiting 83% identity while Cp 
and Cy exhibit 79% identity (45). Unlike the C a and Cp gene, the Cy gene is an 
intronless retroposon gene, which appeared in the human genome an estimated forty 
million years ago (73). Thus, Cy is the only known example of a primate specific PKA 
gene.
C a and Cy differ in gene transcription regulation and substrate and 
pseudosubstrate specificities. Differences in gene transcription regulation were observed
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through transient transfections and luciferase-reporter assays where C a  induced 
transcriptional activation through CREB and Cy did not (105). Differences in 
pseudosubstrate and substrate recognition have been observed where C a  is inhibited by 
protein kinase inhibitor (PKI) while Cy is not (13,20) and Cy exhibits a lower V than
m a x
C a for most substrates tested (20). These differences between C a and Cy suggest that 
while both enzymes are cAMP-dependent, they may fulfill different functions within the 
cell.
The Cy mRNA has been identified only in human testes where it was cloned from 
a human testes cDNA library (45). PKA Cs, or Ca2, has recently been identified as a 
testes specific isoform, a splice variant of C a  expressed in mature sperm (52,107), but 
this isoform is not human specific. Identification of Cy in other tissues has been difficult 
because of the high homology between Cy and C a and the absence of isozyme-specific 
antibodies. Since Cy was identified in testes, a tissue with a high concentration of cells 
undergoing differentiation, it is possible that Cy has a function in cellular differentiation. 
Furthermore, sperm undergo differentiation that involves specific isoforms of the PKA 
catalytic subunits (52). In addition, Cy is an intronless (73) gene, and many intronless 
genes play a role in cellular differentiation (110-116). U-937 myeloid leukemia cells 
were selected as a model system to investigate this possibility. This cell line can be 
induced to differentiate when treated with several cAMP-elevating reagents including 
forskolin and dibutyryl cAMP.
We present evidence for the first time that Cy is expressed in U-937 cells using 
DEAE-Sepharose chromatography separation, kinase assays in the presence and absence
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of PKI, immunoblot analysis with C-subunit isozyme-selective antibodies, and RT-PCR 
coupled with restriction fragment length polymorphism (RFLP) analysis. Three days after 
8-CPT-cAMP induced differentiation, analysis of mRNA, protein, and catalytic activity 
indicated increases of Cy expression. These observations suggest a previously undefined 
function for Cy in cellular differentiation and pose new questions concerning regulation 
of human cell differentiation by PKA catalytic and regulatory isozymes.
MA TER1ALS AND METHODS
Tissue Culture Conditions -  U-937 myeloid leukemia cells were maintained in RPMI
5
1640 with 10% FBS and L-glutamine at a density of 5 x 10 cells/mL, incubated at 37°C 
and 5% C 0 2. For chromatography analysis, kinase assays, immunoblot analysis, and
6
RFLP analysis, 2.4 x 10 cells/mL in 85 mL of growth media were induced to 
differentiate with 50 pM 8-(4-chlorophenylthio) adenosine- 3', 5'- cyclic monophosphate 
(8-CPT-cAMP, 10 mM stock in FLO) for three days.
6
Cell Harvest -  Following a three-day treatment with 8-CPT-cAMP, 204 x 10 U-937 
cells were washed with one volume of isotonic KP buffer (10 mM potassium phosphate, 
1 mM EDTA, 250 mM sucrose, pH [6.9]), sedimented (200 x g, 15 minutes), the 
supernatant discarded, and the cell pellet stored at -80°C until used for chromatography 
analysis. When appropriate, cells were thawed on ice, homogenized with a Dounce 
homogenizer in 2 mL KP buffer without sucrose (low ionic strength KP) containing 
protease inhibitors (10 pg/mL leupeptin, 20 pg/mL pepstatin A, 2 mM 
phenylmethylsulfonyl fluoride, 2 pg/mL trypsin inhibitor and 2 pg/mL aprotonin), 10 
mM 1,4-dithiothreitol, and 50 mM potassium fluoride (a phosphatase inhibitor). Cell lysis 
was assessed microscopically using trypan blue. The homogenate was sedimented
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(15,800 x g, 10 minutes, 4°C), the supernatant removed and kept on ice. One aliquot of 
supernatant was combined with Laemmli sample buffer (1:3, sample buffer: sample), 
incubated at >90°C for 10 minutes and stored at -20°C. The remainder o f the cell extract 
was used for kinase assays and chromatographic separation.
Proliferation Assay -  Proliferation rate decreases as cells differentiate. To use 
proliferation as a differentiation marker, 3000-5000 U-937 cells/well in a 96 well plate 
were treated with 50 pM 8-CPT-cAMP for three days and compared to untreated 
(undifferentiated) cells. Following treatment, cells were incubated 30 minutes with 3- 
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium (MTS, Cell Titer 96 Aqueous One Solution Cell Proliferation Assay, 
Promega), according to the manufacture’s instruction. The optical density was measured 
at 492 nm for each well in a Tecan plate reader, where an increase in absorbance 
corresponds to an increase in cell viability. Data are presented as the mean ± standard 
error (n=5), with significance shown relative to undifferentiated, as determined by a 
Student’s t-test.
Nitrobluetetrazolium Assay -  Nitrobluetetrazolium (NBT) reduction by U-937 cells was 
used to determine respiratory burst activity in cells differentiating toward monocyte-like 
cells. The respiratory burst was also used as a differentiation marker because it includes 
wide range of sophisticated functions that are acquired during differentiation and absent 
in undifferentiated cells. NBT reduction was measured in undifferentiated cells and cells 
treated for 3 days with 50 pM 8-CPT-cAMP. Following three days ± treatment, lxlO6 
cells were incubated at 37°C for 45 minutes with 0.1% NBT and phorbol 12-myristate 
13-acetate (20ng/mL final), applied to a glass slide (Cytospin III centrifuge, Shandon
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Southern; Sewickley, PA), stained with 0.5% safranin, and analyzed microscopically 
under oil immersion. A minimum of 200 cells/slide was counted. Data are presented as 
the mean ± standard error (n=5), with significance shown relative to undifferentiated 
cells, as determined through a Student’s t-test.
DEAE Chromatography Analysis o f  Cell Extracts -  Chromatographic separations were 
performed at 4°C by loading 1.8 mL of cell extract (an average of 7.5 mg/ml protein in 
undifferentiated cells and 0.9 mg/mL in differentiated cells as determined by BioRad’s 
Protein Assay) onto a 4 mL diethylaminoethyl (DEAE)-Sepharose fast-flow resin 
(Pharmacia Biotech) column, that had been pre-equilibrated with 10 column volumes of 
low ionic strength KP buffer. The flow-through was passed over the column three times. 
The extract was eluted with a 50 mL, 0-500 mM NaCl gradient in KP buffer, while 
collecting 1 mL fractions, which were analyzed for kinase activity.
Kinase Assay -  Enzyme activity was measured in crude cell extract and from
32
chromatography samples by measurement o f P -y-ATP incorporation into Kemptide 
(Leu-Arg-Arg-Ala-Ser-Leu-Glu, Bachem Bioscience Inc.) as described previously (24). 
All reactions contained 78 pM Kemptide, ± 10 pM cAMP, ± 1 pM protein kinase 
inhibitor (PKI). Activity was corrected for the total protein in the cell extract and 
expressed as pm ol o f  ATP incorporated/minute/mg total protein in cell extract. 
Immunoblot analysis -  Samples were separated on a 9% SDS-PAGE gels with a 4% 
stacking gel, transferred and treated with antibodies as described previously (105). Three 
different antibodies were used at the indicated dilutions: a rabbit polyclonal antibody to 
Cy from Santa Cruz Biotechnology (sc-905, lot# A297, 1:1000), a polyclonal antibody to 
Cy from Abgent (cat# AP7014a, lot# SH020924K, 1:500), and a Ca-selective monoclonal
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antibody (Transduction Laboratories, cat# P73420, lot# 6, 1:1000). Following primary 
antibody treatment and washes, the membranes were incubated with HRP-conjugated 
anti-mouse or anti-rabbit polyclonal antibodies (Amersham Biosciences) at a 1:1000 
dilution and washed. The membranes were developed using Amersham’s ECL detection 
kit and imaged electronically (BioRad’s VersaDoc imaging system).
U-937 RNA isolation and RT-PCR/ Restriction Fragment Length Polymorphism (RFLP) 
analysis-  This work was done by Dr. Rana C. Morris. Because o f the high homology 
between C a and Cy, including the C ’ un-translated region, it was not possible to 
specifically amplify either of the isoform mRNAs without inclusion of the other. 
However, we were able to differentiate the two based on differences in restriction enzyme
sites in amplified sequences that included both C a  and Cy. Untreated and treated U-937
6
cells were isolated on days 0, 1, 2 and 3. Cell pellets (2x10 cells) were lysed with Trizol 
reagent (Gibco BRL/Invitrogen) and total cellular RNA (RNA ^ was isolated via
phenol/chloroform extraction followed by isopropanol precipitation, washed twice with 
70% ethanol and dissolved in DEPC-treated dH20 . Purity and quantity o f both types of
RNA samples was assessed via UV spectrophotometer at 260 and 280 nm. The A26(/A280
ratios for all RNA isolates were consistently between 1.86 and 1.96.
Reverse transcription was done following manufactures instructions (AMV 
reverse transcriptase, Promega). Five micrograms of RNAfot was subjected to first-strand
synthesis by 30 units of AMV-RT with an 2.5 pg oligo (dT) primer in a total volume of 
25 pL at 48°C for 60 minutes.
PCR primers were generated using sequences from the human cAMP-dependent 
protein kinase catalytic subunits (Ca: NM_002730 and Cy: NM_002732) to amplify a
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portion of PKA-Ca and -Cy based on a highly conserved region between Ca and -Cy, that 
significantly diverges from human Cp (NM_002731, NM_207578, NM_182948). The 
primer set amplifies a 370 base pair region of both C a (284-654nt) and Cy (256-626nt) 
transcripts (forward primer: 5’-CCACTACGCCATGAAGATCCTC-3’ and reverse 
primer: 5 ’-CGCGCTTGGCGAAACCGAAGTC-3 ’).
Five microliters of the RT reaction was added to a standard PCR reaction mixture 
containing 5 units Taq polymerase (Promega) and 2.5 pg of each the forward and reverse 
Ca/Cy-specific primers in a total volume of 25 pL. Negative controls were run to 
determine if any genomic and reagent contamination was present along with positive 
controls, generated by “doping” additional PCR reaction tubes with 1 pg of plasmid-based 
expression vectors for C a and Cy transcripts. A 10-minute 94°C hot start began the 45- 
cycle reaction (30 second 94°C dissociation step, 45 second 58°C annealing step and 90 
second 74°C extension step) with a final 10-minute 74°C extension step added after the
th
45 cycle. PCR products were analyzed by separating 5 pL of each reaction mixture in a 
2% Tris-acetate-EDTA agarose gel before performing the restriction digestion analysis.
Five microliters of the PCR reaction were added to subsequent restriction 
digestions containing 1 unit of Rsal, PstI or Xhol (Promega) in appropriate reaction 
buffers and incubated for 1 to 2 hours at 37°C. Standard glycerol-based DNA sample 
buffer was added to the entire restriction digestion mixture. The samples were applied to 
15% polyacrylamide gels with a 3% stacking gel and separated (30 mA, 4 hours) using a 
Tris-borate-EDTA buffering system. The gels were then rocked at room temperature for 
5 minutes in 200 mL ethidium bromide solution (0.25pg/mL), and imaged using a UV 
transilluminator and a digital camera.
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RESULTS
Differentiation o f  U-93 7 Cells with 8-CPT-cAMP -  The human U-937 myeloid leukemia 
cell line differentiates in response to increases in intracellular levels o f cAMP induced 
with forskolin (176), but not with agonist to G-protein coupled receptors such as 
histamine and dimaprit (176,177). Alternatively, the cells can be treated directly with 
membrane permeable cAMP analogues such as dibutyryl cAMP (dbcAMP) (178,179) to 
bypass adenylyl cyclase. However, dbcAMP breaks down into butyrate (180,181), which 
can also induce differentiation of U-937 cells (180). Another analogue that may be more 
suitable for a cAMP-specific effect is 8-(4-chlorophenylthio) adenosine- 3', 5'- cyclic 
monophosphate (8-CPT-cAMP). To the best of our knowledge there are no published 
reports showing U-937 cells differentiate in response to 8-CPT-cAMP. This analogue has 
no known biologically active byproducts, has a higher affinity for PKA (182,183) and is 
less susceptible to phosphodiesterase (PDE) hydrolysis than dbcAMP (10,184). Dose 
response studies demonstrated that the 8-CPT-cAMP EC5Q was 50 pM for differentiation
of U-937 cells (data not shown).
Markers for U-937 cellular differentiation include a decrease in cellular proliferation and 
DNA synthesis, increase in cell adherence and its associated extracellular markers CD11 
and CD 18, increase in phagocytosis and its associated extracellular marker FcyRII, 
increase in respiratory burst activity, superoxide production, and their associated marker 
CD14 (176,178,179,185-188). For this study we selected two of these markers, which 
include diverse cell functions and have been well established for U-937 cellular 
differentiation: cellular proliferation, which was tested here with an MTS assay, and an 
increase of respiratory burst activity, which was tested with nitroblutetrazolium (NBT).
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Using these methods, a 2.5-fold increase in respiratory burst (Figure 28A) and a 38% 
decrease in cellular proliferation (Figure 28B) were observed in cells treated with 8-CPT- 
cAMP for 3 days. A 30% decrease in cell number was observed in treated cells relative 
to untreated cells by hemocytometer analysis (data not shown), which is in agreement 
with the values obtained from the MTS assay (Figure 28B). There was also no apparent 
difference in cellular viability between treated and untreated cells after three days as 
determined by trypan blue exclusion under a hemocytometer (20% decrease in viability 
in both treated and untreated cells, data not shown). The results from the MTS and NBT 
assays demonstrate that a three-day treatment with 50 pM 8-CPT-cAMP is sufficient to 
initiate differentiation in U-937 cells and these results are in good agreement with 
published work showing U-937 differentiation in the presence o f forskolin and dbcAMP 
(176). Kinase Activity in Whole-Cell Extract -  While Cy, C a, and CP all bind to the 
regulatory subunit and can be specifically differentiated from other kinases by their 
cAMP-dependence, a key difference among them is that C a and Cp are inhibited by PKI 
(ICgo = 5-12 nM (95)) and Cy is not (IC5Q > 90,000 nM (20)). The conditions set for the
kinase assay make the assay very specific for PKA. These include measurement of 
activity in the presence of cAMP and the use o f a PKA-selective substrate used at a 
selective concentration. The use of cAMP in this assay alone makes this assay specific 
for PKA, for of the 518 kinases identified in the human kinome, only one has been 
described as cAMP-dependent, and that is PKA. The difference in PKI-sensitivity 
between the isoforms was exploited here to identify Cy-associated kinase activity in the 
cell. Cy-associated kinase activity is defined here as cAMP-dependent, PKI-insensitive 
kinase activity measured in the presence of the PKA selective substrate,
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F ig . 28. 8-CPT-cAMP induces differentiation in U-937 cells. U-937 cells 
were treated for three days with 50 pM 8-CPT-cAMP and markers for 
differentiation were determined. A, acquisition of respiratory burst activity was 
determined by reduction of Nitrobluetetrazolium and B, proliferation was 
determined using MTS proliferation assays as described in Materials and 
Methods. Bars represent the average of five experiments with (*) indicating 
statistical significance relative to control in each experiment. Error bars 
represent the standard error for each condition.
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Kemptide. This is in contrast to Ca-associated  activity, which is defined as cAMP- 
dependent, PKI-sensitive kinase activity measured in the presence o f Kemptide. 
Measurement of kinase activity in cell extract showed total cAMP-dependent activity did 
not change appreciably in differentiated cells (723 pmol/min/mg) relative to 
undifferentiated cells (703 pmol/min/mg) (Figure 29). Flowever, cAMP-dependent, PKI- 
insensitive activity increased from 186 pmol/min/mg in undifferentiated cells (26% of 
total activity) to 270 pmol/min/mg in differentiated cells (37% of total activity) (Figure 
29). This result suggests an increase in Cy-associated kinase activity during or following 
differentiation.
DEAE Chromatography Profiles o f  Undifferentiated and Differentiated U-937 Cells -  To 
determine the effect o f the cAMP-analogue on U-937 cell’s PKA profile, the extracts of 
treated and untreated cells were separated by DEAE column chromatography. Kinase 
activity profiles were generated using four different conditions (± cAMP, ± PKI) for each 
fraction collected from a 50 mL, 0-500 mM NaCl gradient elution. The profile shows 
that U-937 cells underwent a shift from 36% type I, 64% type II PKA (Figure 30A) in 
undifferentiated cells to 100% type I PKA in differentiated cells (Figure 30B) after three 
days of treatment with 8-CPT-cAMP. The total activity in undifferentiated cells under 
peaks I and II was 6111±1267 pmol/min/mg, while in treated cells the activity shifted 
completely to type I, 7271±1922 pmol/min/mg (±SE, n=3). The total PKI-insensitive 
activity eluted from the DEAE column from undifferentiated cells was 738±146 
pmol/min/mg, while from treated cells this activity was 828±405 pmol/min/mg (±SE, 
n=3).
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F ig . 29. 8-CPT-cAMP-induced differentiation increases Cy-associated 
PKI-insensitivity, cAMP-dependent activity in U-937 ceils. U-937 cells 
were differentiated as described in the legend to Figure 1 and Materials and 
Methods. Protein kinase activity was determined with Kemptided as 
substrate in the presence and absence of cAMP and PKI (see Materials and 
Methods). Each bar is divided into PKI-sensitive (dotted section o f bar) and 
PKI-insensitive (stripped section of bar) activity from total cAMP-dependent 
kinase activity. PKI-insensitive activity is also indicated as a percent of total 
activity above each corresponding condition. Each bar represents an average 
of five experiments and the error bars represent the standard error for each 
condition.
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F ig . 30. 8-CPT-cAMP-induced differentiation of U-937 cells 
shifts the PKA profile to the type I isoform. U-937 cells were 
differentiated as described in the legend to Figure 28 and in the 
Materials and Methods section. Cell extracts were separated by 
DEAE-sepharose chromatography , A, before or, B, after treatment 
with 8-CPT-cAMP and analyzed for Kemptide kinase activity in 
the presence of cAMP (10 pM) and the presence and absence of 
PKI (lpM ). The profiles are representative of three independent 
experiments.
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The DEAE profile also shows that in undifferentiated cells approximately 60% of 
cAMP-dependent, PKI-insensitive activity is associated with type I PKA and remains 
associated with type I PKA in differentiated cells (Figure 30A).
Immunoblot Analysis o f  U-937 Cells -  A difficulty with selectively identifying Cy 
expression in cells and tissues has been the absence o f an antibody that selectively 
detected this isoform. Both PKA catalytic subunits C a and Cy share 83% identity, but 
only 58% identity at the amino terminus (amino acids 1-40). Santa Cruz Biotechnology 
and Abgent developed polyclonal antibodies (pAb) to this region of Cy. These antibodies 
were tested here for selectivity on serially diluted (20-1.25 ng) purified C a and Cy (each 
of 40kDa apparent molecular weight). The antibody from Santa Cruz detected both 
purified recombinant isoforms, while the antibody from Abgent only detected 
recombinant Cy at all protein levels tested except at 1.25ng (Figure 31 A). The only 
discernible difference between C a and Cy with the Santa Cruz antibody is that Cy 
provides a better signal (darker band) than C a, which allowed for cell extracts, the 
antibody, or both to be titrated to the point where the antibody only detected Cy (data not 
shown). However, this approach was not practical since C a is expressed in all tissue 
types, and Cy expression in any tissue type has yet to be characterized other than in 
human testes (45). The Santa Cruz antibody has recently been used to incorrectly identify 
expression of human specific Cy in rat cells (109), indicating the importance of 
demonstrating the selectivity and limitations of these antibodies. Based on our result the 
Abgent antibody was used to probe membranes with extract from differentiated and 
undifferentiated U-937 cells (Figure 3 IB).
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F ig . 31. Immunoblot analysis demonstrates expression of both C a  
and Cy in U-937 cells. A, two commercially available polyclonal 
antibodies made against Cy-peptides were tested against purified 
recombinant Cy and Ca. Lanes were loaded with between 1.25-20 ng of 
protein as indicated by the shaded bar over each blot. B, the Abgent anti- 
Cy-antibody was tested against blots with differentiated and 
undifferentiated U-937 cell extract. The lower pnael in this figure is 
presented as an inverted image to aid visualization of the Cy-band.
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The antibody detected a 40kDa band only in extract from differentiated U-937 cells 
suggesting Cy expression increases during or following differentiation. An anti-Ca 
selective monoclonal antibody (105) was used to determine C a  expression levels before 
and after U-937 differentiation (Figure 3 IB). This antibody detected similar levels of C a 
expressed before and after differentiation, suggesting C a  protein levels do not change 
during the period tested.
RT-PCRJRFLP Analysis o f  U-937 Cells -  Because o f the high homology between C a and 
Cy, it has not been possible to design primers that selectively amplify only one mRNA 
from the two isozymes, something we have attempted numerous times with no success. 
However, the specificity of this RT-PCR allowed for the selective amplification of only 
C a and Cy transcripts in human cells. The primer set used for the PCR step amplifies a 
370 base pair region of both C a (284-654nt) and Cy (256-626nt) transcripts and was 
designed to prevent the amplification of the C(3 isoform. No bands other than the 
expected 370 bp amplicons were observed.
To differentiate the amplicons, an adaptation of the restriction fragment length 
polymorphism (RFLP) protocol was developed (Figure 32A). The C a  amplicon 
sequence does not contain a PstI digestion sequence, but PstI cleaves the Cy amplicon 
into fragments of 254, 86 and 31 base pairs. The restriction enzyme Xhol does not cut the 
Cy amplicon but cleaves the C a amplicon into fragments of 255 and 116 base pairs. In 
addition, the restriction enzyme Rsal cleaves both amplicons, yielding different 
fragments o f 207 and 164 base pairs for C a, with 149, 106, and 101 base pairs for Cy. 
The Rsal reaction would also serve to identify any potential amplification of the C(3
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isoforms, since expected patterns for this fragment are bands of 165 and 106 base pairs. 
These contaminating bands were not observed.
Both C a and Cy RT-PCR/RFLP fragments were detected in control U-937 cells. 
Ca-specific fragments were seen as Rsal digests o f 206 and 165bp (data not shown), 
Xhol digests o f 255 and 116bp, and the band not cut by PstI (Figure 32B). The Cy- 
specific fragments were seen as Rsal digests of 148, 106, and lOlbp (data not shown), 
PstI digests of 254, 86bp and 31bp, and the band not cut by Xhol (Figure 32C). The RT- 
PCR/RFLP analysis o f undifferentiated and differentiated U-937 cells demonstrated that 
both C a and Cy RT-PCR fragments are seen on days zero through day two in untreated 
and treated U-937 cells (Figure 32B). However, by day three, Cy RT-PCR/RFLP 
fragments were still visible while no apparent C a transcripts were detected in treated U- 
937 cells (Figure 32C).
DISCUSSION
Until now Cy was believed to be a testes-specific PKA isoform, identified only 
through the cloning of its mRNA. Here for the first time we demonstrate the expression 
of active endogenous Cy protein from an in-cell system. The hypothesis put forth in this 
paper was that Cy expression occurs in cells undergoing differentiation, regardless of the 
cell’s tissue source. Here we present, for the first time, evidence that Cy is expressed in 
cells from tissues other than the testes. Furthermore, because Cy mRNA is present before 
differentiation, and protein expression and kinase activity increases following 
differentiation, it is possible that Cy has a function in cellular differentiation. U-937 cells 
are a human histiocytic lymphoma cell line (189),
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F ig . 32. Differential expression of C a and Cy mRNA in U937 cells during 
8-CPT-cAMP induced differentiation. Control and 50 pM 8-CPT-cAMP- 
treated U-937 cells were isolated on days 0, 1, 2, and 3 and total RNA was 
isolated as described in Materials and Methods. A, scheme o f expected 
fragments from restriction enzyme digest of RNA for each isoform as indicated 
to the right of the figure. Restriction enzyme digests of RT-PCR products was 
done using, B, Xho I or, C, Pst I for analysis of C a and Cy expression, 
respectively. Each gel is representative of three independent experiments.
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a transformed pre-monocytic cell line that has retained some pre-monocyte 
characteristics but capable of fully differentiating. About 20-30%
of the cells in culture exhibit differentiation markers at any given time, such as 
phagocytic activity and the expression o f Fc receptors (189).However this cell line is 
considered by many to be a useful model for cellular differentiation because o f its 
increased response to pro-differentiation agents such as TPA, IFNy and cAMP, while not 
becoming terminally differentiated. We utilized the cAMP-PKA pathway to induce U- 
937 cell differentiation and investigate Cy expression during cellular differentiation. 
Cellular differentiation was determined through two well-characterized differentiation 
markers that include highly specialized functions exhibited by differentiated cells. These 
included cell growth arrest and increased respiratory burst activity. U-937 cells exhibit 
differentiation markers when treated with cAMP-signaling pathway agonist such as 
forskolin and dbcAMP (176,185,190), but there are inherent problems with each of these 
reagents, such as metabolic byproducts and degradation of endogenous cAMP by PDE. 
Therefore, we opted to use 8-CPT-cAMP, another membrane permeable, cAMP- 
analogue, which was less susceptible to degradation by cAMP PDE (10). Three days of 
treatment with 8-CPT-cAMP induced reduced cell growth rate without decreasing 
cellular viability, while increasing the cell’s respiratory-burst activity. Both markers are 
used to identify pre-monocytic cellular differentiation to macrophages. While 
differentiation of U-937 cells with a cAMP analogue has been described before, this is 
the first time it has been demonstrated with 8-CPT-cAMP and the first time that Cy 
expression at the mRNA and protein level have been detected in any cell.
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An increase in cAMP-dependent, PKI-insensitive kinase activity was measured in 
U-937 cells treated three days with 8-CPT-cAMP, suggesting an increase in Cy protein 
expression following differentiation. While the apparent increase in Cy activity may 
appear modest, changes in cAMP-dependent functions do not require large changes in 
cAMP or PKA enzyme activity. Furthermore, total cAMP-dependent kinase activity did 
not increase. Since the maximal velocity of Cy is significantly lower than that o f C a  (20), 
the real change in Cy activity may be underestimated based on a comparison with Ca. In 
addition, Cy does not bind PKI and therefore will not be exported from the nucleus by the 
same mechanism for Ca. Thus the real impact of Cy expression on transcription is 
uncertain. While transcriptional regulation by the two isozymes is different, the real role 
for Cy-regulated transcription remains to be determined, but difference may be related to 
cell events such as cellular differentiation. While it has been demonstrated that Cy 
appears to be more PKG-like, preferring substrates with differences on the carboxyl- 
termini o f the phosphorylation site (20), the physiological meaning for differences in 
substrate specificity between the isozymes in vivo remains to be determined. What 
remains perplexing is a potential role for Cy that is specific to primates.
A more readily recognized change following U-937 cell differentiation was the 
PKA profile, which shifted from a type I: type II ratio of 0.64 in undifferentiated cells to 
100% type I in differentiated cells, with Cy activity prevalently associated to type I PKA. 
A similar trend has been observed in Chinese hamster ovary (CHO) cells treated with 
dbcAMP (7), although the loss of type II PKA following treatment with dbcAMP was not 
as dramatic in CHO cells. This is mostly likely due to differences in cell types. CHO is a 
hamster epithelial cell line and U-937 is a human hematopoietic cell line. Increases in
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Riot in response to treatment with cAMP analogues have also been observed in cultured 
fibroblast and Rat-1 cells (7). This implies that an increase in intracellular cAMP serves 
as a positive feedback signal for R Ia  expression, and that R Ia  is part of the cell’s 
differentiation mechanism. However, PKA function in cellular differentiation is still not 
clear.
The stable level of total kinase activity present in the cell before and after 
differentiation suggests that a basal pool of potential PKA activity is maintained in the 
cell irrespective of the cell’s differentiation status. Maintenance of total PKA activity 
levels in the cell may be achieved through compensation by differential expression of the 
catalytic subunit isoforms. An example of this is seen in C(31 knockout mice, where total 
kinase activity does not decrease in the absence of Cpi (58), suggesting that Ca 
compensates for the loss of C(31. Thus, an increase in Cy expression in U-937 cells during 
differentiation may be offset by a decrease in C a expression to maintain a constant 
kinase activity level in the cell. This is supported by the result showing C a, but not Cy, 
mRNA decreased following three days of treatment with 8-CPT-cAMP, while C a protein 
levels did not decrease based on immunoreactivity with the putative C a  antibody. The 
possible presence of C a protein in the absence of its RNA may be due to the stability of 
the PKA catalytic subunit, which has a 9.2 hour half-life when bound to the regulatory 
subunit (79). Alternatively, it is possible that the cAMP-dependent, PKI-sensitive activity 
observed post-differentiation is due to Cp, since immunoreactivity between C a and CP 
with these antibodies has not been verified. While there is no precedent for CP 
compensation for a loss in C a, C-subunit isozyme shifts have not been closely analyzed 
in a differentiation paradigm. However, a compensation of Cy for C a activity would
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require a considerable increase in Cy catalytic activity since the V is at least 10 times
m ax
lower than the C a (20). Nevertheless, about 90% of PKI-sensitive activity in U-937
cells was present in the holoenzyme form (activity ratios were 0.04 in untreated cells and 
0.13 in treated cells, data not shown). Based on these results, further analysis of C- 
subunit isozymes during U-937 cell differentiation is warranted. It is especially 
noteworthy that Cy catalytic activity and immunoreactivity increases after 8-CPT-cAMP - 
mediated differentiation in U-937.
One major advance and important development demonstrated here is the 
identification of an antibody that is relatively specific for Cy that has allowed the 
unequivocal differentiation of the Cy- and Ca-subunit isoforms. Antibodies to 
specifically identify Cp remain unavailable. The Cy antibody detected a 39-40 kDa band 
that appeared following, but not prior to, differentiation and was concurrent with the 
increase in Cy-associated kinase catalytic activity. The antibody did not detect this band 
prior to differentiation, possibly because Cy expression levels were below the detection 
limit of the antibody. The kinase assay used is very sensitive (10) and thus, likely to 
detect Cy-catalytic activity before an antibody detects the protein. While immunoblot 
analysis with different antibodies does not allow quantification o f C-subunits, the 
increase in cAMP-dependent, PKI-insensitive kemptide kinase activity following 
differentiation provides a valuable tool to differentiate and quantify changes in Cy 
activity. The low PKI-insensitive specific activity relative to PKI-sensitive, cAMP- 
dependent activity may be due to low Cy expression levels and/or lower Cy relative
to C a (20). Thus, while it is clear that Cy expression increases following differentiation,
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because the two isozymes are so different kinetically, it is problematic to compare them 
on an activity basis. It is intriguing that the homology o f the two isozymes is so high, yet 
specific identification of their respective mRNAs is problematic. Thus, it has not been 
possible readily to differentiate and quantify the mRNA levels of Cy and Ca. While C a 
and Cp have higher homology than Cy and C a, there are differences that complicate 
specific Cy identification. First, differences between Cy and C a  do no occur in clusters, 
but are spread out through the sequence, making it difficult to find specific primers. In 
addition, C a and Cp can be easily differentiated in their 3’ un-translated sequences, 
which are highly homologous in Cy and Ca. Clues to differences in transcription targets, 
which are likely to reveal potential roles for Cy in differentiation, have also been difficult. 
However, potential differences in compartmentalization provide further avenues for 
investigation. Because Cy appears preferentially to associate with the RI subunit, the type 
I PKA is often predominant in differentiated tissues, and the different localization of type 
I and type II (191), suggest that compartmentalization of type I-Cy is likely to play a 
functional role that remains to be determined. It is interesting in this regard that activation 
o f type I PKA is sufficient to inhibit T lymphocyte proliferation (192).
The presence of Cy in the primate genome for 40 million-years suggests a 
potential role for this cAMP-dependent, PKI-insensitive kinase in human function and the 
result here suggest a role in differentiation. However, it cannot be ruled out that it is a 
human genome remnant that has not experienced evolutionary selective pressure. The 
function of Cy in the cell remains to be unequivocally elucidated but the results presented 
here and elsewhere (13,20,105) suggest that differences observed between Cy and C a in 
stable transfections (5) and in vitro biochemical experiments (20) may manifest
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themselves during cellular processes such as cellular differentiation. Cy-association with 
type I PKA, the only isoform present following differentiation, the increase in Cy- 
associated activity following differentiation, and the presence of Cy mRNA before and 
after differentiation all support the idea that Cy may have a function in cellular 
differentiation that is distinct from the other isoforms.
Identification of functional Cy protein expressed in the cell completes the Cy 
central dogma (i.e. gene expresses the messenger RNA, which in turn expresses the 
functional protein) where the gene (106) and mRNA (45) had previously been identified 
in the cell. Presented here are the concurrent identification of both the mRNA and the 
protein in the U-937 cell line. The presence o f Cy mRNA before and after differentiation 
hints at the possibility for Cy post-transcriptional regulation, something suggested for 
R Ia (reviewed in (193)). This would add another regulatory step for this isoform; other 
steps include transcriptional (through a CG-rich promoter) and post-translational (via 
phosphorylation) regulation. Now that an antibody selective for Cy is available, it may be 
possible to study the dynamics of Cy expression and localization in the cell in order to 
understand regulation of this isoform. While this work raises many questions about Cy it 
clearly demonstrates for the first time that functional Cy is expressed in human cells 
during a very specific cellular process.
The results indicated here suggest that there is a switch in both R and C-subunit 
isoforms during the cAMP differentiation program in U-937 cells. However, the 
regulation of R- and C-subunit levels is obscure. The C-subunits are downstream of 
TATA-less promoters, which are often regulated as housekeeping genes and associated 
with constitutive expression. Thus, the levels of the subunits themselves may be regulated
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at the level o f mRNA and/or protein. C a protein has a half-life o f less than 10 hours, 
suggesting that the protein is turned over rapidly, but turnover before and after 
differentiation in U-937 cells has not been analyzed. It is interesting that three days after 
initiation of differentiation by 8-CPT-cAMP, the C a mRNA is not observed while the 
presence of cAMP-dependent, PKI-sensitive activity is present. It is not clear at this time 
if this is due to C a  and/or Cp activity, but it is possible that the C a  mRNA is turned over 
rapidly as it is in S49 cells (79, 80), while Cy continues to be expressed.
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CHAPTER VI 
SUMMARY AND CONCLUSIONS
SUMMARY
The ideas for the work addressed in this dissertation came from two sources. The 
first one was from a National Institute of Health Grant (GM44777) awarded to Dr. 
Stephen J. Beebe designed to study C a and Cy in order to understand protein kinases 
structure-function relationships in this protein family, which is one of the largest groups 
o f evolutionarily conserved protein families in the human genome. The second source 
was an American Physiological Society Pre-Doctoral Porter Fellowship for Minorities 
awarded to this Ph.D. candidate. Within this fellowship three specific aims were outlined 
to address this dissertation, which came out this Ph.D. candidate understanding the theory 
and specific aims described and outlined in Dr. Beebe’s NIH Grant. The three specific 
aims addressed in this dissertation were: 1) to identify differences in primary structure 
between PKA-Cy and PKA-Ca that defines their physiological function in intact cells 
(Chapter II); 2) to characterize post-translational differences between purified PKA-Cy 
and PKA-Ca that defines their physiological function (Chapter III); and 3) to characterize 
the kinetic mechanism for PKA-Cy through determination of the rate constants for each 
catalytic step of the phospho-transferase reaction (Chapter IV). The results from a fourth 
objective were presented here, which was to address the question, is Cy expressed in 
differentiating cells? (Chapter V). The work presented in chapters III and V is currently 
being submitted for publication, thus each chapter was presented in this dissertation in the
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format o f an independent manuscript to facilitate extracting each chapter for publication 
purposes. This work also follows up on research initiated by Dr. Wei Qing Zhang done 
for his dissertation under the guidance Dr. Stephen J. Beebe. To the best of my 
knowledge there is currently nobody else doing research that focuses on characterizing 
the PKA-Cy catalytic subunit. Following are summaries of the findings presented in this 
dissertation (Chapters II-V). The summaries are derived from the abstracts presented at 
the beginning of each chapter.
Specific Aim 1: To identify differences in primary structure between PKA-Cy and PKA- 
C a that defines their physiological function in intact cells (Chapter II )-  This hypothesis 
was tested here with chimera constructs wherein the first 50 and terminal 70 amino acids 
were swapped between C a  and Cy and tested through transient transfections with CREB- 
mediated reporter assays. While both isoforms induced transcriptional activation, the 
chimera transfections failed to exhibit any activity in COS7 cells, but exhibited some 
activity in Kin8 cells. This difference in cell type dependent activity may suggest that 
there are cell type specific factors that are required for the proper expression of the 
chimeras. Immunoblot analysis demonstrated that each of the chimeras was expressed in 
COS7 cells and sequence analysis of the constructs suggests that the expressed chimeras 
should have the expected primary sequence. While it is difficult to interpret the results 
obtained from the chimera studies the amino and carboxyl terminals remain important 
regions of divergence between C a and Cy that warrant further studies.
Specific Aim 2: To characterize post-translational differences between purified PKA-Cy 
and PKA-Ca that defines their physiological function (Chapter III)-  Differences in 
phosphorylation between C a and Cy were studied here through reporter assays using Cy
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
132
and C a T197 point mutants, immunoblot analysis using an anti-phospho T197 selective 
antibody and LC-MS/MS phosphomapping of purified recombinant proteins. Two novel 
phosphorylation sites were identified on both isoforms by LC-MS/MS analysis (Cy pS14 
and C a and Cy pS259). It was also determined that Cy is phosphorylated homologously 
to mammalian expressed C a (pT197 and pS338) and the modification at T197 is 
important to the function of both isoforms suggesting that differences in post- 
translational modification are not the reason for kinetics differences observed between 
these two isoforms.
Specific Aim 3: To characterize the kinetic mechanism fo r  PKA-Cy through determination 
o f  the rate constants fo r  each catalytic step o f  the phosphotransferase reaction (Chapter 
IV )-  Here recombinant C a  and Cy binding rates for ATP and ADP were compared 
through stopped-flow analysis, using ATP and ADP conjugated to a N- 
methylanthraniloyl (mant) fluorophore. Using this approach the Ca-ATP on and off rates 
were determined and found to be in good agreement with the literature. The C a  release of 
ADP was slower than the release of ATP, which is in agreement with ADP release being 
the rate-limiting step. However, several other slow rates were measured for both the 
mant-ATP on and off rates, which may suggest that mant-ATP is not the rate-limiting 
step. But the work presented here was unable to clarify this question. The homogenous 
purification of recombinant hisg-Cy proved to be difficult but enough was attained to 
measure the Cy ADP-off rate, a step where divergence in the catalytic mechanism of 
these two isoforms could explain differences in biochemical function. The signal 
measured for the Cy ADP off-rate was reproducible but very low and needs to be 
repeated in another independent experiment. However, the measured ADP-off rate for C a
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is about 9-times faster than that of Cy, a result that is in agreement with differences in 
their steady-state kinetics. While it is still not clear what structural differences between 
C a and Cy lead to functional differences it is encouraging to identify a difference in their 
catalytic rate. The physiological ramifications of the biochemical difference between Ca  
and Cy still needs to be determined through studies of the isoforms in vivo and in the 
intact cell.
Is Cy expressed in differentiating cells? (Chapter V)- For the first time we present the 
selective identification of endogenous Cy protein and mRNA expressed in human U-937 
cells. Increases in protein kinase inhibitor (PKI)-insensitive, cAMP-dependent kinase 
activity following 8-CPT-cAMP-induced differentiation of U-937 cells suggested an 
increase in Cy expression during differentiation, while total PKA catalytic activity did not 
change. A new Cy-specific antibody identified a 40-kDa band following differentiation of 
U-937 cells and RT-PCR/RFLP analysis demonstrated that Cy mRNA was present before 
and after differentiation. DEAE chromatographic analysis of U-937 cells showed that the 
PICA profile changed from similar levels of type I and type II PKA in undifferentiated 
cells to 100% type I in differentiated U-937 cells. Furthermore, 60% of PKI-insensitive, 
cAMP-dependent activity in U-937 cells was associated with type I PKA suggesting Cy 
favors association with type I PKA in this cell line. These results expand our 
understanding of structure-function roles for PKA isoforms in cell differentiation and 
function. Furthermore the increase in Cy expression during U-937 differentiation suggests 
a novel function for Cy in the cell.
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CONCLUSIONS
In order to identify causes for biochemical differences between C a  and Cy both 
the primary structure and modified structure of C a and Cy were compared and 
characterized. The two isoforms were also characterized for differences in their catalytic 
mechanism and analyzed for expression patterns in the cell. The results from the chimera 
studies, where portions of the amino or carboxyl terminals were swapped between C a 
and Cy, remain inconclusive. This makes it hard to interpret the significance of the amino 
and carboxyl terminal regions to the function of the catalytic subunits. Studies of these 
regions have been done successfully with C a through the characterization of point 
mutants and have demonstrated that these regions are important to the enzymes stability 
and substrate recognition. As Cy seems to be more labile than C a  but still functional, it 
seems likely that differences in these regions will eventually help address physical 
differences between C a and Cy that contribute to their functional differences. The amino 
terminus is of particular interest because this region is where there is the greatest 
divergence from homology between C a and Cy and among C-subunit isoforms among 
species. Furthermore the amino terminus contributes to overall structural stability o f Ca. 
Because the C a amino and carboxyl domains fall outside of the conserved kinase 
catalytic core it is difficult to draw from studies on these regions in other kinases. In most 
kinases these regions are a lot more extensive than in C a  and Cy and the functions for 
these domains are very diverse, ranging from protein-protein interactions, localization 
signals, and regulatory functions, depending on the kinase.
A feature conserved amongst most kinases is the phosphorylation of the catalytic 
loop. Most, if  not all, kinases need to be phosphorylated in this region to be active. And
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many o f them need to be phosphorylated on the catalytic loop to be fully functional. 
Studying the phosphorylation state o f C a and Cy addresses an important question: can a 
kinase be active in the absence of phosphorylaion on its catalytic loop? Because 
phosphorylation differences on the catalytic loop were not found between C a  and Cy, 
which is the only modification shown to date to be o f significance to the function both 
isoforms, functional differences between C a and Cy do not seem to be due to 
phosphorylation differences. Two novel phosphorylation modifications were identified 
on Cy and C a and it will be of interest in future studies to determine if these 
modifications are important to the function of either catalytic subunit. It will also be of 
interest to compare these modifications with other kinases to determine if  these are 
conserved among other kinases. Thus, the studies presented in the Chapters II and III 
have not demonstrated physical differences between the catalytic subunits to which 
functional differences can be attributed.
A likely explanation for functional differences was observed upon studying the 
catalytic mechanisms of each C-subunit. The catalytic mechanism for C a has been 
studied in great detail, and while the literature clearly favors an ordered Bi Bi mechanism 
with the release of ADP as the rate-limiting step, it is also clear from the same literature 
that many questions remain about this mechanism. Here it was found that the “rate- 
limiting” step is much slower for Cy than for Ca. Thus, it is very possible that functional 
differences are due to differences in their ADP off-rates. The simple explanation for this 
observation is that C a  and Cy exhibit differences in their overall tertiary-structure, which 
may affect the conformation of the isoforms and binding of the substrates. This 
measurement may explain why Cy exhibits slower kinetic and reporter activities as these
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mechanisms depend on phosphorylation by the C-subunits. Thus Cy would phosphorylate
0.1 of the substrate molecules that C a would, causing a ten-fold difference in kinetic or 
reporter-activity measured, which is what is observed in most instances.
The most elusive fact about Cy has been the absence of its expression identified in 
the cell. Here for the first time Cy expression has been identified in differentiating cells. 
The appearance of Cy in differentiated U-937 cells suggests a novel role for PKA in this 
cellular process.
While the results presented here fail to identify specific physical differences that 
could define functional differences between C a and Cy, the same results have helped us 
understand the significance of phosphorylation to the catalytic loop of the enzyme, for 
without this modification both kinases lost all of their function. Furthermore, Cy is a 
functional kinase that is expressed in the cell during specific cellular events such as 
differentiation, and has survived 40 million years in the human genome. So while the 
nature o f Cy function in the cell remains elusive, it is likely that the manifestation of the 
functional differences between C a and Cy will eventually be observed when the tools to 
knock out Cy or C a without disrupting the other isoform are developed. But the present 
results suggest that during some cellular events, such as differentiation, it seems 
important that a cAMP-dependent kinase with slower kinetics and reporter activity than 
C a  be expressed, while C a expression be suppressed.
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APPENDIX A
PERSONAL COMMUNICATION FROM TONY HUNTER ON THE ORIGIN OF 
THE TERM KINASE
Dear Dr. Hunter,
I am a graduate student in Dr. Stephen Beebe's laboratory characterizing PKA-Cgamma. 
You may not recall but we met very briefly at a second messenger Gordon Research 
Conference in 2001. I have enjoyed reading many of your reviews and learned a great 
deal through these. Recently I have been curios about the history o f kinases, when they 
were first discovered and where the name "kinase" came from as this is not a proper 
name for an enzyme, according to IUBMB, as kinases are phospho-transferases. Could 
you recommend a good source or reference from which to obtain this type of information 
on kinases. The earliest publication I could find in PubMed with kinase in it was 1963, 
and this was a German paper, I do not recall the authors. I would appreciate any 
information you could share with me on this matter.
Sincerely, Gary
From: Tony Hunter [mailto:hunter@salk.edu]
Sent: Thursday, January 30, 2003 9:20 PM 
To: Morris, Gary Z.
Subject: Re: Question about the origin of the name "kinase"(?)
Gary - You really need to address this question to one of the old timers in the field like 
Ed Krebs, but I'll give it a shot. Although
phosphoproteins had been known since the 1930's, the first protein kinase activity to be 
detected was casein kinase (actually we now know this was CK2) by Kennedy in 1954 
(JBC 207:153; JBC 211:969; see Annu. Rev. Biochem. 61:1). For a history of protein 
phosphorylation, you might look at Cohen (Nature Cell Biol. 4:E127). The word kinase 
derives from the Greek kinein, which means to move towards, and in this context it is 
moving the phosphate from ATP onto an acceptor (e.g. hexose or protein). I hope that 
this is helpful. Tony
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APPENDIX B
CONSTRUCTION OF CHIMERAS
 O r ig in a l  M e s s a g e -------
From: zhang98 [mailto:zhang98@uic.edu]
Sent: Monday, November 11, 2002 12:31 PM 
To: Beebe, Stephen
Subject: construction of C-subunit chimera 
Hi Dr. Beebe:
I am sending you the procedure how to make those chimera as 
attached file and the following. Any question, please call me. thans.
John
Construction o f Ca Chimera containing cDNA encoding aal to aa 50 of 
Cg sequence and Cg Chimera containing cDNA encording aal to aa 50 
of Ca sequence:
Human Ca an d Cg chimera cDNA were subcloned via the Hindlll and EcoRI sites into 
the pCMV5 (Invitrogen). The splicing sites of the chimeras mapped to highly 
differeciated regions of PKA catalytic subunits (the first 50 amino acids sequence). The 
chimeric constructs were then generated by repeated cycles o f two-step polymerase chain 
reaction overlap extension (Horton et al 1989) with the Ca and Cg cDNA containing 
plasmids as templates, espectively. The cDNAs were fused sequentially at homology 
regions of splicing site RS with the primers listed in Table I. Primers Ca-A/Cg-A and 
Ca-D Cg-D provided Hind III and EcoRI linkers, respectively, for subcloning into 
pCMV5. The correct sequence of the final products was confirmed by automated 
sequencing.
Table
Oligonucleotide primers for splicing by overlap extension polymerase chain reaction. For 
the internal primers, the bold primer sequence letter denote the locations of the 
corresponding splicing sites coding sequences or their reverse complements, respectively.
Name Sequence Sense/antisense 
Internal primers
Ca-B 5' CTGGTGCCTCACCAGCATCACTCGCCCAAAGGAGCCGGT (s)
Cg sequence for overlapping 
Ca-C 5'ATGCTGGTGAAGCACAAGGAG (AS)
Cg-B 5' CTTGTGCTTCACCAGCATCACCCGCCCGAAGGAGCCCAT (S)
Ca sequence for overlapping 
Cg-C 5'ATGCTGGTGAGGCACCAGGAG (AS)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
External primers
Ca-A 5 '-ATATAAGCTTATGGGCAACGCCGCCGCCGCC (S) 
Ca-D 5'-ATATGGATCC CTAAAACTCAGTAAACTCCTT (AS) 
Cg-A 5'-ATATAAGCTTATGGGCAACGCCCCCGCCAAG (S) 
Cg-D 5 '-AT AT GG ATCCCT A A A ACT C AG A A A ACT CCTT (AS)
 Original Message-----
From: zhang98 [mailto:zhang98@uic.edu]
Sent: Wednesday, September 22, 2004 11:17 AM 
To: Morris, Gary Z.
Subject: RE: Hey John
Hey Gary:
Sorry for the delay because thing up here become pretty taugh. Now I 
am sending you the sequence I designed for Chimera at 280 aa after.
1) Cg-a-5' (1 )CAAGAACTCCAAGGGTTTGCGCTTGGTGAGGTCCAC
2)Cg-a- 5 '(2) A A ACCCTT GG AGTTCTT GGGGGT C A AT G AC AT C A AG
3)Ca-g-5'(l)CAAGGACTCCAAAGGCTTGGCGCTTGGTGAGATCCAC
4)Ca-g-5;(2)AAGCCTTTGGAGTCCTTGGGGGTTGGCGACATCAAG 
Please take a look and synthesize them in HPLC scale. Send them to
me while you have them. I will let people done as soon as possible.
Thanks.
Regards
John
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APPENDIX C
ELSEVIER COPYRIGHT PERMISSION
w
Nfri; ivmnicinnrate the founding 
u f  ik e  1 lo o se  n f  KUcvii in 1 
a n c  c e i e h u ic  ih e  c s u h  u  . .n  m
OS I . t l £  I ’i i C v i C t  C O L H jJU J . 1) .‘‘ S i t .
16 June 2005 Our ref: HG/mm/jun 05.J063
Mr Neil Reece 
ReeceNM@CHKD.COM 
For: Gary Morris
Dear Mr Morris
ARCHIVES OF BIOCHEMISTRY & BIOPHYSICS, Vol 403, pp 219-228, Morris et 
al, "Differential..." 1 Figure only
As per your letter dated 6 June 2005, we hereby grant you permission to reprint the 
aforementioned material at no charge in your thesis subject to the following conditions:
1. If any part o f the material to be used (for example, figures) has appeared in our 
publication with credit or acknowledgement to another source, permission must 
also be sought from that source. If such permission is not obtained then that 
material may not be included in your publication/copies.
2. Suitable acknowledgment to the source must be made, either as a footnote or in a 
reference list at the end of your publication, as follows:
"Reprinted from Publication title, Vol number, Author(s), Title o f article, Pages 
No., Copyright (Year), with permission from Elsevier".
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3. Reproduction of this material is confined to the purpose for which permission is 
hereby given.
4. This permission is granted for non-exclusive world English rights only. For other 
languages please reapply separately for each one required. Permission excludes 
use in an electronic form. Should you have a specific electronic project in mind 
please reapply for permission.
5. This includes permission for UMI to supply single copies, on demand, of the 
complete thesis. Should your thesis be published commercially, please reapply 
for permission.
Yours sincerely
Helen Gainford 
Rights Manager
Your future requests will be handled more quickly if you complete the 
online form at www.elsevier.com/locate/perm issions
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
158
APPENDIX D
DETERMINATION OF TRANSFECTION EFFICIENCY
Fluorescent image o f  COS7 cells transfected with a pCMV5 RI-GFP 
expression vector to determine transfection efficiency using Fugene 6. 
Transfection efficiency was determined as a percent by the ratio of 
fluorescent cells counted under fluorescent light over total cells counted 
under white light in the same field (xlOOO magnification, under oil 
emersion, on a Ziess Axioscope fluorescent microscope). A minimum of 
200 cells/transfection experiment were counted. The transfection 
efficiency was determined to be 22 ± 5 % (average ± standard deviation).
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APPENDIX E
EQUATION TO DEFINE RATE-LIMITING STEP DIFFERENCE BETWEEN C a  
AND Cy
 Original Message-----
From: Howard White [mailto:howard_white@hotmail.com]
Sent: Tuesday, June 14, 2005 3:54 AM 
To: MorrisGZ@CHKD.COM 
Subject: RE: rate limiting step for PKA
I must say that I didn't recall that we obtained a reasonably ok result with gamma. 
Assuming that was the case there could be a relationship between the ADP 
dissociation and steady state rates - but I need to reread the papers. Could you 
either send me a pdf or the reference to the work from the San Diego lab on mant 
kinetics? In general the following sort of mechanism would produce parallel 
dependances o f ADP dissociation and steady state rates.
K k-ADP
M*-ADP <==> M-ADP —> M  + ADP
ksteadstate = K x  k-ADP
where K = 0.1 of some steps prior to ADP dissociation is unchanged and k-ADP 
is the measured rate o f ADP dissociation. There are other possibilities.
I hope this is of some help.
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APPENDIX F
MEASURING STOKES RADII OF PURIFIED RECOMBINANT CATALYTIC 
SUBUNITS
W. Zhang, G. Z. Morris, S. J. Beebe (2004) Protein Expression and Purification (35)
pp. 156-169.
The Stokes radii (Rs) and molecular weight (MW) for each purified recombinant 
catalytic subunit were measured using their elution constant (Kavg). The Kavg for each 
subunit was determined as follows: Kavg = (Ve-V0)/(Vr V0)  where Ve is the elution volume 
of the protein, Vt is the total volume of the column, and V„ is the column void volume 
determined by the elution volume of blue dextran. A standard curve of V(-log Kavg) vs. 
Stokes radii of the standard was used to calculate the Stokes radii of each catalytic 
subunit. The standards used to generate each curve were ferritin (440 kD, 61 A), aldolase 
(158 kD 48.1 A), albumin (67 kD, 35.5 A), ovalbumin (43 kD, 30.5 A), 
chymotrypsinogen (25 kD, 20.9 A), myoglobin (20.2 kD, 20.2 A), and cytochrome C 
(11.7 kD, 17 A).
The correlation coefficient for the Stokes radii was 0.93. These parameters were 
determined from a Sephacryl S-300 (320 mL) gel filtration column (Amersham 
Bioscience). Four mL fractions were collected and analyzed by measuring OD@280 nm 
(Perkin Elmer Lambda 40 uv/vis spectrophotometer). Results were plotted as elution 
volume vs OD, and the peak elution for each standard was used as its Ve. Analysis of C a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and Cy was carried out during purification following the CM-Sepharose chromatography 
and from crude extract with no difference observed on the measured Kavg between the 
two sample forms. C a and Cy fractions were tested for catalytic activity using a standard 
kinase assay. Total volume loaded onto column for each run was lm L (~ 0.3% of total 
column volume).
The Stoke’s radii for C a was measured at 27.5 ± 0.4 A and for Cy at 24.2 
± 0.8 A (the p-value = 0.02).
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APPENDIX G
THROMBIN DIGEST CHARACTERIZATION OF C a AND Cy
A  th r o m b in  d ig e s t  o f  p u r if ie d  r e c o m b in a n t  C a  a n d  C y  w a s  d o n e  w i t h  I n g / p L  C -s u b u n it  
and 1U of thrombin (Sigma) in a final volume of 50 pL o f KP10EDTA1 [6.9] and 
incubated at 37°C for one hour. The reaction was stopped by adding 50 pL sample buffer 
and incubating at >90°C for 10 minutes. The samples were analyzed by running 5 ng of 
C-subunit from each reaction on a 9% acrylamide gel with 4% stacker, transferring to a 
PVDF membrane, and treating with a rabbit polyclonal antibody against the carboxyl 
terminal o f C a (Santa Cruz Biotechnology) that cross-reacts with both isoforms. The 
membrane was incubated with ECL reagent (Amersham Biosciences), imaged by 
exposing film to the ECL treated membrane.
The figure shows that thrombin cleaves the hisio-tag off o f C a, which contains an 
RGD thrombin cleavage sequence. But Cy disappears all together with thrombin 
treatment and it is not clear why, as the antibody recognizes the C-subunit carboxyl 
terminal and the Cy-thrombin cleavage site is on the amino terminus.
Cy C a  C a  Cy C a  C a  
Cy Thrombin Tx q ,—  >
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APPENDIX H
DETERMINING C a KM FOR ATP USING PROMEGA’S NON-RADIOACTIVE 
KINASE ASSAY
The non-radioactive kinase assay was done according to manufacture’s protocol 
(PepTag® Assay for Non-Radioactive Detection of Protein Kinase C or cAMP Dependent 
Protein Kinase catalogue # 5340). Briefly, lpL  of pure recombinant C a  (2pg/ml) in PKA 
dilution buffer (350mM K3P04 (pH 7.5) O.lmM DTT) was mixed with 5pi PepTag® 
PKA 5X reaction buffer (lOOmM Tris-HCl (pH 7.4) 50mM MgCl2), 5pl PepTag® 
AlPeptide, and 9pL water in a 0.5ml microcentrifuge tube and kept on ice until 5pl of 
the corresponding ATP concentration was added (0-100 pM, final concentrations). The 
reaction was initiated by the addition of ATP and incubating at 30°C for 30 minutes. 
Incubating in a heating block at 
95°C for 10 minutes terminated the 
reaction. Glycerol ( lp l of 80%) was 
added to each sample following 
incubation. Samples were then 
loaded into a 1% agarose gel and 
run at 25V until phosphorylated and non-phosphorylated PepTags were resolved in gel. 
The gel was imaged on a VersaDoc (BioRad) and the band intensity was determined 
using Quantity One software (BioRad). An Eadie-Hofstee plot was generated from this 
data using Band intensity (y-axis) vs. [ATP]/band. The slope of this curve represents the
phosphorylated
2 ng cPKAa with varying 
concentrations of ATP
ooo
un-phosphorylated
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measured C a  Km for ATP, which was determined here at 14 pM. This measure is in good 
agreement with the published value (25 pM, Zhang et al Protein Expression and 
Purification (2004) 35, 156-169).
E adie-H ofstee Plot for cPK A a w ith A TP, B ased on R esults from N on-radioactive
K inase A ssay
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APPENDIX I
cAMP, KING OF SECOND MESSANGERS
Yon w or l wlfli calcium? TaRfc a how and felss If!
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APPENDIX J
STOPPED-FLOW MEASURE OF Ca-MANT-ATP ASSOCIATION RATE IN THE 
PRESENCE OF THE PHOSPHO-ACCEPTOR SUBSTRATE, KEMPTIDE
400
350
y = -0.1961x + 296.43 
R2 = 0.3865-  300 
©
« 250
V5
2 200 
0^
I  150esa>
g
100
y = -0.0063x + 11.038 
R2 = 0.0278
400200 3001000
(micromolar Kemptide)
The mant-ATP on rate for C a  was measured here at 25°C in the presence of Kemptide to 
determine whether the presence of the second substrate affected the observed binding rate 
of the first substrate. This was done by mixing 13 pM Ca  from one syringe with 100 pM 
mant-ATP mixed with varying concentrations of Kemptide (25-400 pM) in the other 
syringe. The slopes for the two rates measured at 25°C, k l (open circles) and k2, (closed 
circles) decreased very slightly with increasing amounts of Kemptide (klKemptide: y = -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
167
0.1961x + 296.43, R2 = 0.3865; k2 Kemptide: y = -0.0063x + 11.038, R2 = 0.0278), but it is 
not clear if  these slopes fall within the error measured for each rate. A similar trend is 
observed in the amplitudes for each rate (amplitude 1 Kemptide: y = -O.OOOlx - 0.1012, R = 
0.5346; amplitude2KemPtide: y = -7 x 10'6x + 0.0123, R2 = 0.085). The correlation values 
for these curve fits are not very good, suggesting that there is little difference between the 
measured rates or amplitudes at each Kemptide concentration.
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APPENDIX K 
CALCIUM, KING OF SECOND MESSENGERS
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